Mehrdad Kevin Ariani, MD
Cardiovascular Disease (Cardiology) · Northridge
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 36 years
- Graduated 1990
Offices
2 locations · Center for Advanced Cardiac and Vascular Interventions · 13 clinicians in this group
Looking this up.
Hospitals listed: Northridge Hospital Medical Center · Providence Cedars Sinai Tarzana Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ariani’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A48708 · Current
Licensed to practise in California · since 1990 · expires 2027-11-30 · Tehran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Northridge Hospital Medical CenterNorthridge, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.11, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.147, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Providence Cedars Sinai Tarzana Medical CenterTarzana, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.439, Oct 2024 – Sep 2025
See every measure and the patient survey for Northridge Hospital Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.11 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.147 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.13 to 2.13) · 1,012 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.78 (0.44 to 1.11) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.43 (96.43 to 190.42) · 88 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 457 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.4 · 384 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 315 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 3,091 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.05 to 0.44) · 6,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 6,139 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.28 to 3.34) · 1,193 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.26 (0 to 15.07) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.14 (2.11 to 10.16) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.14) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.76) · 5,578 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 139 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 1.041 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 674 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 27.2 · 214 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.2 · 563 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.8 · 438 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 484 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.1 to 7.4) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (6.8 to 13.8) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.9 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 141 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 165 cases | No different | Jan 2024 – Dec 2024 |
What patients said (621 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Providence Cedars Sinai Tarzana Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 8 the same, 0 worse of 8 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.439 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.04 to 1.89) · 1,345 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.82 (0.52 to 1.12) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 144.61 (88.03 to 201.2) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4.2 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 517 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.7 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 153 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,946 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.38) · 6,836 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,140 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.01 (0.01 to 4.01) · 1,608 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.43 (0.9 to 3.96) · 650 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.26 (0.84 to 3.69) · 1,494 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.01 (1.78 to 14.24) · 690 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.73 to 8.71) · 687 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.46 to 3.39) · 382 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.92) · 5,423 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 202 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.299 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.416 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.714 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 195 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 623 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -14 · 183 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 4.6 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 8 · 452 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 455 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 207 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.9 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 192 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 544 cases | No different | Jan 2024 – Dec 2024 |
What patients said (511 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$1,084,131
Medicare paid this office $1,084,131 for 1,187 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 699 | $165,767 | $104 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 86 | $153,786 | $1,788 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 496 | $89,034 | $170 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 86 | $73,996 | $430 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 250 | $42,886 | $148 |
See all 48 services
| Return visit (30+ min) | 699 | $165,767 | $104 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 86 | $153,786 | $1,788 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 496 | $89,034 | $170 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 86 | $73,996 | $430 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 250 | $42,886 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 161 | $34,321 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 206 | $30,068 | $101 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 71 | $29,407 | $414 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 15 | $28,628 | $1,590 |
| Long return visit (40+ min) | 159 | $24,186 | $138 |
| New patient visit (45+ min) | 176 | $23,094 | $131 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 27 | $14,487 | $453 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 68 | $13,934 | $186 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 212 | $12,949 | $58 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 67 | $11,402 | $161 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 54 | $11,304 | $209 |
| Nuclear medicine study of heart muscle blood flow by pet | 86 | $10,962 | $127 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 71 | $10,823 | $76 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 31 | $10,390 | $43 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 156 | $9,946 | $63 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 30 | $9,311 | $44 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 631 | $8,178 | $12 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 18 | $7,474 | $415 |
| Ultrasound of leg arteries or artery grafts | 29 | $7,408 | $224 |
| Ultrasound of both sides of head and neck blood flow | 38 | $6,527 | $172 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 67 | $5,298 | $40 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 29 | $4,777 | $36 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 25 | $3,999 | $154 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 59 | $3,744 | $23 |
| Ultrasound of leg arteries at rest and after exercise | 27 | $3,742 | $121 |
| Programming of dual lead pacemaker system | 34 | $3,292 | $69 |
| Injection of drug or substance into vein | 80 | $2,801 | $35 |
| Ultrasound of heart blood flow, valves and chambers | 54 | $2,564 | $47 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 25 | $2,110 | $78 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 93 | $1,972 | $10 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 14 | $1,810 | $113 |
| Injection, regadenoson, 0.1 mg | 137 | $1,506 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 54 | $1,223 | $23 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 18 | $1,072 | $60 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 46 | $969 | $21 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $700 | $26 |
| Insertion of needle into vein for collection of blood sample | 62 | $623 | $9 |
| Heart rhythm recording of continous external ekg over 8-15 days | 46 | $510 | $11 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 16 | $340 | $20 |
| Ultrasonic guidance for blood vessel access | 23 | $282 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 19 | $216 | $11 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 11 | $214 | $19 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 17 | $210 | $12 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 79 | More than 93% of doctors who do this |
| Leg revascularization (restoring blood flow) | 32 | More than 85% of doctors who do this |
| Pacemaker insertion or repair | 33 | More than 81% of doctors who do this |
| Varicose vein removal | 15 | More than 51% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 31 | 18 | 51 | 58 | – | – |
| Insertion of needle into vein (3 years or older) | 18 | – | 53 | 58 | – | – |
| Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | 34 | – | 37 | 35 | – | – |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 32 | 16 | 23 | 20 | – | – |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 24 | 12 | 17 | – | – | 18 |
| Insertion of pacemaker and upper and lower heart chamber electrode | – | – | 11 | 13 | 16 | 18 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,187 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 25% · Women 54% · Also on Medicaid 59% · Health risk score 1.82. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 65% · Diabetes 58% · Depression 39% · Chronic kidney disease 38% · Heart failure 37% · Atrial fibrillation 32% · COPD 25% · Dementia 23% · Cancer 16% · Stroke 15%.
The office billed $3,978,215, Medicare allowed $1,399,432 and paid $1,084,131; for 8,051 services of 122 kinds; $1,506 of it was for drugs given in the office and $1,082,626 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,187 | 8,051 | 78 | 1.82 | $3,978,215 | $1,084,131 |
| 2023 | 1,157 | 8,086 | 78 | 1.86 | $4,038,270 | $1,026,770 |
| 2022 | 1,222 | 8,849 | 77 | 1.88 | $4,457,665 | $1,225,492 |
| 2021 | 1,111 | 7,724 | 77 | 1.74 | $4,388,685 | $1,255,273 |
| 2020 | 1,023 | 7,313 | 77 | 1.81 | $3,705,665 | $1,089,362 |
| 2019 | 1,079 | 8,220 | 77 | 1.88 | $4,292,558 | $1,344,845 |
| 2018 | 1,072 | 7,404 | 77 | 1.87 | $4,754,435 | $1,270,049 |
| 2017 | 996 | 5,785 | 77 | 1.90 | $3,012,485 | $807,933 |
| 2016 | 1,018 | 6,278 | 77 | 1.98 | $2,272,100 | $687,680 |
| 2015 | 1,025 | 5,470 | 77 | 1.84 | $1,652,285 | $546,622 |
| 2014 | 1,104 | 5,317 | 77 | 1.97 | $1,467,500 | $510,173 |
| 2013 | 1,131 | 5,642 | 78 | 2.00 | $1,374,095 | $444,108 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 54 services
| Return visit (30+ min) | 656 | $151,956 | $104 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 453 | $80,370 | $170 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 113 | $45,684 | $404 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 26 | $45,315 | $1,743 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 246 | $41,431 | $142 |
| Long return visit (40+ min) | 273 | $40,954 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 163 | $31,156 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 208 | $29,543 | $100 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 34 | $28,384 | $417 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 38 | $22,587 | $461 |
| New patient visit (45+ min) | 165 | $21,080 | $128 |
| Injection, regadenoson, 0.1 mg | 131 | $19,242 | None |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 81 | $16,214 | $180 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 107 | $14,739 | $69 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 221 | $13,218 | $57 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 56 | $11,291 | $202 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 73 | $11,127 | $76 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 52 | $9,187 | $173 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 25 | $8,822 | $45 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 147 | $8,568 | $58 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 39 | $8,410 | $54 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 25 | $8,408 | $41 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 556 | $7,481 | $12 |
| Ultrasound of both sides of head and neck blood flow | 40 | $6,971 | $174 |
| Ultrasound of leg arteries or artery grafts | 23 | $6,603 | $228 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $6,444 | $403 |
| Balloon dilation of single coronary artery or branch | 11 | $4,528 | $412 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 25 | $3,722 | $149 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 51 | $3,609 | $24 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 36 | $3,346 | $78 |
| Ultrasound of leg arteries at rest and after exercise | 23 | $3,269 | $117 |
| Nuclear medicine study of heart muscle blood flow by pet | 26 | $3,238 | $125 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 14 | $2,874 | $205 |
| Ultrasound of heart blood flow, valves and chambers | 56 | $2,630 | $47 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 118 | $2,576 | $10 |
| Programming of dual lead pacemaker system | 27 | $2,400 | $69 |
| New patient visit (60+ min) | 13 | $1,681 | $129 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 12 | $1,369 | $114 |
| Drug infusion during cardiac catheterization | 16 | $1,324 | $83 |
| Programming of dual lead implantable defibrillator system | 14 | $1,323 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 56 | $1,248 | $22 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,103 | $85 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 11 | $1,100 | $20 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 48 | $1,085 | $22 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $1,039 | $27 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 15 | $894 | $60 |
| Injection of drug or substance into vein | 25 | $871 | $35 |
| Heart rhythm recording of continous external ekg over 8-15 days | 48 | $557 | $11 |
| Insertion of needle into vein for collection of blood sample | 49 | $479 | $8 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 25 | $442 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 23 | $267 | $12 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 25 | $244 | $10 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $154 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $27 | $2 |
2022: 54 services
| Return visit (30+ min) | 665 | $138,749 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 500 | $90,896 | $176 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 58 | $79,916 | $1,378 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 142 | $60,438 | $426 |
| Long return visit (40+ min) | 291 | $57,332 | $146 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 61 | $50,961 | $418 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 247 | $47,501 | $164 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 11 | $41,681 | $719 |
| Injection, regadenoson, 0.1 mg | 188 | $36,088 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 187 | $34,324 | $61 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 142 | $32,446 | $57 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 53 | $30,812 | $481 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 245 | $26,981 | $86 |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 11 | $19,248 | $962 |
| New patient visit (45+ min) | 134 | $17,157 | $128 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 84 | $16,135 | $177 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 216 | $12,871 | $58 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 130 | $12,684 | $49 |
| Ultrasound of leg arteries or artery grafts | 48 | $12,530 | $228 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 202 | $12,026 | $59 |
| Ultrasound of both sides of head and neck blood flow | 69 | $11,898 | $172 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 59 | $11,049 | $187 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 58 | $10,516 | $170 |
| New patient visit (60+ min) | 49 | $9,544 | $195 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 560 | $7,513 | $11 |
| Ultrasound of leg arteries at rest and after exercise | 46 | $6,324 | $119 |
| Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | 11 | $5,535 | $158 |
| Short return visit (20+ min) | 68 | $5,237 | $75 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $4,924 | $379 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 17 | $3,763 | $52 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 22 | $3,566 | $162 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 16 | $3,387 | $45 |
| Ultrasound of heart blood flow, valves and chambers | 59 | $2,872 | $49 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 14 | $2,677 | $191 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 45 | $2,623 | $22 |
| Programming of dual lead pacemaker system | 26 | $2,144 | $63 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 14 | $2,126 | $125 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 104 | $2,119 | $11 |
| Drug infusion during cardiac catheterization | 21 | $1,873 | $85 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 18 | $1,605 | $80 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 24 | $1,532 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 59 | $1,362 | $23 |
| Injection of drug or substance into vein | 32 | $1,191 | $37 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $1,134 | $31 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $1,005 | $21 |
| Ultrasonic guidance for blood vessel access | 11 | $816 | $37 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 34 | $727 | $21 |
| Insertion of needle into vein (3 years or older) | 11 | $469 | $8 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 34 | $458 | $13 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 15 | $314 | $21 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 16 | $285 | $18 |
| Insertion of needle into vein for collection of blood sample | 58 | $195 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 15 | $188 | $13 |
| Heart rhythm recording of continous external ekg over 8-15 days | 14 | $173 | $12 |
2021: 54 services
| Removal of plaque in artery of leg, initial vessel | 13 | $182,263 | $10,126 |
| Return visit (30+ min) | 688 | $161,773 | $95 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 67 | $93,958 | $1,402 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 398 | $75,936 | $185 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 67 | $56,084 | $419 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 214 | $44,541 | $171 |
| Long return visit (40+ min) | 235 | $39,056 | $143 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 14 | $38,481 | $755 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 75 | $34,499 | $454 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 141 | $33,942 | $62 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 15 | $31,051 | $1,827 |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 14 | $24,979 | $1,086 |
| Injection, regadenoson, 0.1 mg | 130 | $24,205 | None |
| New patient visit (45+ min) | 182 | $24,079 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 177 | $23,384 | $89 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 34 | $19,151 | $456 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 75 | $17,804 | $69 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 67 | $13,971 | $194 |
| Ultrasound of leg arteries or artery grafts | 48 | $13,367 | $235 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 58 | $12,681 | $219 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 190 | $11,366 | $59 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 61 | $11,314 | $180 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 143 | $8,749 | $61 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 73 | $7,967 | $71 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 534 | $7,784 | $12 |
| Ultrasound of leg arteries at rest and after exercise | 47 | $7,578 | $126 |
| Ultrasound of both sides of head and neck blood flow | 39 | $7,078 | $181 |
| Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | 14 | $6,282 | $170 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,684 | $426 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 16 | $3,746 | $220 |
| Programming of dual lead pacemaker system | 32 | $3,660 | $69 |
| Review by radiologist of abdominal aorta and both leg arteries image | 13 | $3,324 | $151 |
| Ultrasound of heart blood flow, valves and chambers | 58 | $2,927 | $50 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 20 | $2,875 | $144 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 21 | $2,795 | $112 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 40 | $2,514 | $24 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 12 | $1,754 | $117 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 11 | $1,514 | $138 |
| Short return visit (20+ min) | 23 | $1,506 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 58 | $1,399 | $24 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 15 | $1,311 | $82 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 86 | $1,251 | $11 |
| Drug infusion during cardiac catheterization | 12 | $1,120 | $86 |
| Ultrasonic guidance for blood vessel access | 14 | $982 | $35 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $960 | $31 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 13 | $815 | $63 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 13 | $530 | $41 |
| Ultrasonic guidance for blood vessel access | 41 | $529 | $12 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $524 | $24 |
| Insertion of needle into vein (3 years or older) | 14 | $426 | $8 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 19 | $391 | $21 |
| Insertion of needle into vein for collection of blood sample | 89 | $348 | $3 |
| Heart rhythm recording of continous external ekg over 8-15 days | 21 | $319 | $15 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 19 | $259 | $14 |
2020: 48 services
| Return visit (30+ min) | 660 | $131,017 | $80 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 80 | $114,081 | $1,426 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 370 | $69,512 | $179 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 80 | $66,159 | $413 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 85 | $37,130 | $437 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 159 | $29,825 | $168 |
| Injection, regadenoson, 0.1 mg | 157 | $28,285 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 85 | $23,905 | $94 |
| Long return visit (40+ min) | 169 | $23,850 | $114 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 11 | $21,504 | $1,792 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 110 | $20,710 | $62 |
| New patient visit (45+ min) | 178 | $20,413 | $115 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 85 | $19,396 | $57 |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 11 | $18,043 | $1,128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 133 | $15,095 | $88 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 72 | $14,814 | $206 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 22 | $13,769 | $459 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 13 | $13,690 | $761 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 57 | $12,054 | $191 |
| Ultrasound of both sides of head and neck blood flow | 63 | $10,832 | $172 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 55 | $10,376 | $179 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 165 | $10,001 | $60 |
| Ultrasound of leg arteries or artery grafts | 37 | $9,473 | $231 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 150 | $9,371 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 470 | $7,722 | $13 |
| Ultrasound of leg arteries at rest and after exercise | 36 | $4,755 | $122 |
| Programming of dual lead pacemaker system | 49 | $4,613 | $57 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 18 | $4,128 | $217 |
| Ultrasound of heart blood flow, valves and chambers | 72 | $3,552 | $49 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 17 | $2,433 | $143 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 30 | $2,370 | $76 |
| Review by radiologist of arm or leg artery image | 12 | $2,304 | $144 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 15 | $2,041 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 72 | $1,683 | $23 |
| Short return visit (20+ min) | 23 | $1,254 | $52 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 14 | $1,047 | $22 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 83 | $1,002 | $11 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 12 | $986 | $82 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 21 | $873 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $858 | $48 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 13 | $825 | $63 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $605 | $34 |
| Insertion of needle into vein for collection of blood sample | 117 | $462 | $3 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 12 | $446 | $10 |
| External ekg recording for more than 48 hours up to 21 days | 18 | $443 | $25 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 19 | $441 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 11 | $290 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 12 | $155 | $13 |
2019: 55 services
| Removal of plaque in arteries of leg | 11 | $174,032 | $11,602 |
| Removal of plaque in artery of leg, initial vessel | 13 | $139,149 | $8,185 |
| Return visit (30+ min) | 681 | $127,316 | $83 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 51 | $68,778 | $1,349 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 367 | $67,398 | $178 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 125 | $53,833 | $424 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 20 | $45,451 | $1,894 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 51 | $41,719 | $409 |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 23 | $38,349 | $1,198 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 125 | $34,285 | $90 |
| Injection, regadenoson, 0.1 mg | 162 | $29,692 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 145 | $28,298 | $166 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 125 | $27,715 | $55 |
| New patient visit (45+ min) | 205 | $25,704 | $125 |
| Long return visit (40+ min) | 171 | $24,900 | $117 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 20 | $22,466 | $725 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 87 | $16,736 | $192 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 74 | $13,711 | $174 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 27 | $13,440 | $463 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 91 | $11,821 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 109 | $11,654 | $88 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 56 | $11,464 | $194 |
| Ultrasound of leg arteries or artery grafts | 43 | $11,452 | $234 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 176 | $10,209 | $57 |
| Ultrasound of both sides of head and neck blood flow | 48 | $8,775 | $179 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $8,224 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 513 | $7,877 | $14 |
| Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | 15 | $6,111 | $180 |
| Ultrasound of leg arteries at rest and after exercise | 43 | $5,782 | $118 |
| Programming of dual lead pacemaker system | 56 | $5,074 | $54 |
| Review by radiologist of arm or leg artery image | 21 | $4,657 | $150 |
| Ultrasound of heart blood flow, valves and chambers | 86 | $4,153 | $48 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 15 | $2,995 | $200 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 17 | $2,861 | $159 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 40 | $2,709 | $68 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 16 | $2,531 | $158 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 22 | $2,481 | $99 |
| Review by radiologist of abdominal aorta and both leg arteries image | 14 | $2,383 | $149 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 29 | $1,994 | $46 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 86 | $1,994 | $23 |
| Ultrasound of one leg arteries or artery grafts | 13 | $1,840 | $123 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 11 | $1,635 | $149 |
| Ultrasonic guidance for blood vessel access | 24 | $1,224 | $31 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 27 | $1,161 | $10 |
| Short return visit (20+ min) | 16 | $1,041 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 79 | $911 | $10 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $861 | $22 |
| Injection of drug or substance into vein | 13 | $725 | $36 |
| Injection of drug or substance into artery | 12 | $326 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 17 | $324 | $19 |
| Insertion of needle into vein for collection of blood sample | 71 | $262 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $255 | $13 |
| Ultrasonic guidance for blood vessel access | 15 | $196 | $12 |
| Insertion of needle into vein (3 years or older) | 11 | $141 | $8 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15 | $68 | $0 |
2018: 57 services
| Removal of plaque in artery of leg, initial vessel | 18 | $224,348 | $7,237 |
| Removal of plaque in arteries of leg | 13 | $203,448 | $9,688 |
| Return visit (30+ min) | 691 | $133,456 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 389 | $70,310 | $176 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 149 | $65,319 | $435 |
| Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | 23 | $44,528 | $1,272 |
| Chemical destruction of first incompetent vein of arm or leg using imaging guidance | 22 | $44,019 | $1,914 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 23 | $30,143 | $718 |
| Long return visit (40+ min) | 192 | $27,437 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 150 | $26,042 | $160 |
| New patient visit (45+ min) | 215 | $25,535 | $119 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 109 | $20,133 | $172 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 91 | $18,089 | $199 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 122 | $17,833 | $65 |
| Ultrasound of leg arteries or artery grafts | 66 | $16,632 | $225 |
| Injection, regadenoson, 0.1 mg | 135 | $16,261 | None |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 149 | $14,108 | $25 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 26 | $13,990 | $451 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $12,926 | $60 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 55 | $10,788 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $10,250 | $85 |
| Ultrasound of leg arteries at rest and after exercise | 66 | $8,911 | $120 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 42 | $7,233 | $168 |
| Ultrasound of both sides of head and neck blood flow | 36 | $6,940 | $178 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 102 | $5,877 | $55 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 94 | $5,218 | $55 |
| Ultrasound evaluation of blood vessel with review by radiologist, each additional vessel | 18 | $5,154 | $184 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 340 | $5,079 | $13 |
| Programming of dual lead pacemaker system | 58 | $4,507 | $46 |
| Ultrasound of heart blood flow, valves and chambers | 91 | $4,333 | $48 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 18 | $4,004 | $222 |
| Review by radiologist of abdominal aorta and both leg arteries image | 17 | $3,761 | $150 |
| Review by radiologist of arm or leg artery image | 14 | $3,189 | $152 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 22 | $2,859 | $102 |
| Ultrasound of one leg arteries or artery grafts | 12 | $2,590 | $123 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 28 | $2,368 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 91 | $2,095 | $23 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 28 | $1,984 | $68 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $1,973 | $47 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 11 | $1,674 | $152 |
| Programming of multiple lead implantable defibrillator system | 11 | $1,665 | $67 |
| Injection of drug or substance into vein | 20 | $1,483 | $42 |
| Programming of dual lead implantable defibrillator system | 13 | $1,340 | $56 |
| Short return visit (20+ min) | 21 | $1,240 | $56 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 13 | $1,094 | $78 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 14 | $1,094 | $78 |
| Ultrasonic guidance for blood vessel access | 23 | $1,094 | $28 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $999 | $91 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 83 | $886 | $10 |
| Injection of drug or substance into artery | 20 | $598 | $17 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 23 | $577 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 20 | $350 | $17 |
| Insertion of needle into vein for collection of blood sample | 82 | $318 | $3 |
| Insertion of needle into vein (3 years or older) | 20 | $276 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $234 | $12 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $168 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $29 | $3 |
2017: 47 services
| Return visit (30+ min) | 631 | $113,319 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 302 | $60,017 | $194 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 124 | $53,315 | $430 |
| New patient visit (45+ min) | 163 | $20,402 | $125 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 84 | $20,014 | $235 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $19,722 | $166 |
| Long return visit (40+ min) | 147 | $19,612 | $111 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 12 | $19,372 | $1,384 |
| Injection, regadenoson, 0.1 mg | 107 | $18,434 | None |
| Ultrasound study of arm or leg veins with compression and maneuvers | 76 | $13,624 | $175 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 26 | $13,351 | $460 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 11 | $12,964 | $682 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 125 | $12,945 | $26 |
| Ultrasound of leg arteries or artery grafts | 40 | $10,970 | $233 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 126 | $10,907 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $9,784 | $61 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 47 | $8,632 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $6,743 | $88 |
| Ultrasound of leg arteries at rest and after exercise | 40 | $5,708 | $124 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 366 | $5,498 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $5,130 | $48 |
| Ultrasound of both sides of head and neck blood flow | 28 | $5,099 | $182 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 74 | $4,992 | $67 |
| Programming of dual lead pacemaker system | 71 | $4,773 | $37 |
| Ultrasound of heart blood flow, valves and chambers | 84 | $4,108 | $48 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 14 | $3,018 | $216 |
| New patient visit (60+ min) | 16 | $2,702 | $169 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 84 | $1,969 | $23 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 12 | $1,740 | $145 |
| Programming of multiple lead implantable defibrillator system | 11 | $1,683 | $62 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 14 | $1,648 | $110 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,610 | $67 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 13 | $1,060 | $82 |
| Injection of drug or substance into vein | 11 | $888 | $52 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 71 | $857 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $793 | $47 |
| Short return visit (20+ min) | 11 | $573 | $52 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 11 | $566 | $47 |
| Ultrasonic guidance for blood vessel access | 11 | $477 | $28 |
| Insertion of needle into vein for collection of blood sample | 68 | $332 | $3 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 17 | $317 | $19 |
| Injection of drug or substance into artery | 11 | $290 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 19 | $288 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 19 | $193 | $10 |
| Administration of influenza virus vaccine | 17 | $167 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 11 | $161 | $10 |
| Insertion of needle into vein (3 years or older) | 11 | $142 | $7 |
2016: 41 services
| Return visit (30+ min) | 667 | $142,293 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 343 | $69,754 | $198 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 135 | $59,237 | $439 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 21 | $34,937 | $1,397 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 142 | $28,488 | $171 |
| New patient visit (45+ min) | 174 | $21,852 | $126 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 84 | $20,041 | $233 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 32 | $19,410 | $485 |
| Injection, regadenoson, 0.1 mg | 110 | $18,041 | None |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 68 | $15,430 | $211 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 81 | $13,795 | $166 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 137 | $13,701 | $26 |
| Long return visit (40+ min) | 103 | $13,535 | $115 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 137 | $11,779 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $11,540 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $10,870 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 133 | $8,728 | $66 |
| Ultrasound study of veins of both arms or legs including assessment of functional maneuvers | 78 | $6,883 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 108 | $5,878 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 327 | $5,407 | $14 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 20 | $5,271 | $220 |
| Programming of dual lead pacemaker system | 68 | $4,640 | $39 |
| Ultrasound of heart blood flow, valves and chambers | 86 | $4,236 | $48 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 24 | $4,208 | $175 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 13 | $4,023 | $309 |
| Ultrasound of both sides of head and neck blood flow | 22 | $3,676 | $167 |
| Ultrasound of leg arteries or artery grafts | 21 | $3,625 | $173 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 21 | $2,860 | $110 |
| Ultrasound of leg arteries at rest and after exercise | 21 | $2,683 | $128 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 27 | $2,295 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 86 | $2,045 | $23 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,806 | $75 |
| Short return visit (20+ min) | 31 | $1,796 | $58 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,140 | $104 |
| Programming of dual lead implantable defibrillator system | 12 | $1,028 | $57 |
| Insertion of needle into vein for collection of blood sample | 91 | $506 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 23 | $417 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 17 | $410 | $24 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 16 | $298 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 23 | $271 | $12 |
| Administration of influenza virus vaccine | 12 | $118 | $10 |
2015: 38 services
| Return visit (30+ min) | 661 | $144,136 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 315 | $63,492 | $195 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 119 | $52,350 | $436 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 151 | $28,383 | $165 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 19 | $28,048 | $1,336 |
| New patient visit (45+ min) | 199 | $25,663 | $129 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 74 | $17,002 | $230 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 83 | $14,908 | $177 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 65 | $14,580 | $221 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 22 | $11,677 | $508 |
| Injection, regadenoson, 0.1 mg | 102 | $10,783 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 121 | $10,611 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $10,528 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $10,230 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 121 | $7,238 | $59 |
| Ultrasound study of veins of both arms or legs including assessment of functional maneuvers | 79 | $7,001 | $88 |
| Long return visit (40+ min) | 61 | $6,721 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 118 | $5,731 | $48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 344 | $5,657 | $14 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,372 | $448 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 121 | $5,100 | $17 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 19 | $4,659 | $245 |
| Ultrasound of both sides of head and neck blood flow | 27 | $4,616 | $171 |
| Programming of dual lead pacemaker system | 58 | $3,783 | $40 |
| Ultrasound of leg arteries or artery grafts | 19 | $3,780 | $199 |
| Ultrasound of heart blood flow, valves and chambers | 74 | $3,567 | $48 |
| Ultrasound of leg arteries at rest and after exercise | 19 | $2,481 | $131 |
| Evaluation of single or dual chamber pacing cardioverter-defibrillator and generator at time of implantation or replacement | 13 | $2,282 | $163 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $2,148 | $77 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 75 | $1,783 | $24 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 14 | $1,651 | $110 |
| Short return visit (20+ min) | 24 | $1,450 | $58 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 11 | $922 | $84 |
| Administration of influenza virus vaccine | 25 | $688 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 34 | $645 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 35 | $432 | $12 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 25 | $387 | $15 |
| Insertion of needle into vein for collection of blood sample | 86 | $368 | $3 |
2014: 35 services
| Return visit (30+ min) | 614 | $120,092 | $81 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 30 | $54,878 | $1,524 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 260 | $52,346 | $198 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 111 | $47,569 | $429 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 170 | $30,426 | $161 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 172 | $20,916 | $59 |
| New patient visit (45+ min) | 132 | $16,113 | $122 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 27 | $15,208 | $475 |
| Injection, regadenoson, 0.1 mg | 88 | $14,615 | None |
| Ultrasound study of arm or leg veins with compression and maneuvers | 78 | $13,683 | $163 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 52 | $11,145 | $210 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 46 | $10,685 | $232 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 204 | $10,548 | $49 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 111 | $9,669 | $87 |
| Ultrasound study of veins of both arms or legs including assessment of functional maneuvers | 74 | $7,474 | $87 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 111 | $7,130 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 112 | $6,441 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 244 | $3,931 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $3,651 | $85 |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,093 | $172 |
| Programming of dual lead pacemaker system | 68 | $3,070 | $29 |
| Long return visit (40+ min) | 27 | $2,854 | $106 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 25 | $2,794 | $96 |
| Ultrasound of leg arteries or artery grafts | 11 | $2,272 | $207 |
| Ultrasound of heart blood flow, valves and chambers | 46 | $2,146 | $47 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $1,880 | $67 |
| Short return visit (20+ min) | 23 | $1,421 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 46 | $1,037 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 54 | $911 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 54 | $600 | $11 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 25 | $375 | $15 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 15 | $341 | $21 |
| Injection of drug or substance under skin or into muscle | 14 | $309 | $22 |
| Insertion of needle into vein for collection of blood sample | 72 | $306 | $3 |
| Administration of influenza virus vaccine | 24 | $225 | $9 |
2013: 37 services
| Return visit (30+ min) | 599 | $119,997 | $84 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 130 | $59,537 | $435 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 250 | $41,379 | $160 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 149 | $24,665 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 194 | $22,030 | $58 |
| Injection, regadenoson, 0.1 mg | 106 | $17,920 | None |
| New patient visit (45+ min) | 107 | $13,853 | $129 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 129 | $11,476 | $87 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 235 | $11,341 | $47 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 51 | $11,205 | $215 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 17 | $9,207 | $400 |
| Thallium tl-201 thallous chloride, diagnostic, per millicurie | 129 | $8,298 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 130 | $8,037 | $60 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 38 | $7,424 | $195 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 261 | $4,757 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $4,036 | $81 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 16 | $3,533 | $208 |
| Programming of dual lead pacemaker system | 68 | $3,448 | $29 |
| Short return visit (20+ min) | 61 | $3,431 | $54 |
| Ultrasound of both sides of head and neck blood flow | 20 | $3,235 | $162 |
| Long return visit (40+ min) | 23 | $3,119 | $120 |
| Injection of drug or substance under skin or into muscle | 129 | $3,012 | $23 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 16 | $2,729 | $161 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 129 | $2,648 | $20 |
| Initial hospital care with same-day admission and discharge with high level of medical decision making, per day at least 85 minutes | 12 | $2,102 | $175 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 25 | $1,839 | $71 |
| Ultrasound of heart blood flow, valves and chambers | 38 | $1,537 | $39 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 15 | $1,160 | $72 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 14 | $1,106 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 48 | $804 | $16 |
| Programming of dual lead implantable defibrillator system | 11 | $784 | $37 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | $693 | $18 |
| Hospital discharge day management, 30 minutes or less | 12 | $676 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 50 | $561 | $11 |
| Insertion of needle into vein for collection of blood sample | 95 | $481 | $3 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 19 | $275 | $14 |
| Administration of influenza virus vaccine | 19 | $186 | $10 |
Medicaid work
$15,675 in 2024
Medicaid paid $15,675 for 780 billed services this clinician did in 2024, up to 37 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 211 | $9,487 |
| Return visit (30+ min) | 322 | $3,157 |
| 1ST HOSP IP/OBS HIGH 75 | 53 | $1,755 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 47 | $704 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 147 | $572 |
| 2024 | 780 | 5 | 37 | $15,675 |
| 2023 | 810 | 7 | 34 | $18,954 |
| 2022 | 676 | 6 | 34 | $23,794 |
| 2021 | 138 | 2 | 15 | $6,662 |
| 2020 | 216 | 2 | 20 | $5,468 |
| 2019 | 616 | 8 | 26 | $1,862 |
| 2018 | 431 | 4 | 40 | $5,813 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 243 | $11,880 |
| Return visit (30+ min) | 326 | $3,931 |
| Long return visit (40+ min) | 27 | $1,272 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 155 | $760 |
| 1ST HOSP IP/OBS HIGH 75 | 17 | $726 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 16 | $210 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 26 | $173 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 203 | $10,016 |
| Return visit (30+ min) | 267 | $9,571 |
| 1ST HOSP IP/OBS HIGH 75 | 16 | $1,976 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 56 | $1,388 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 118 | $511 |
| Long return visit (40+ min) | 16 | $332 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 70 | $4,064 |
| Return visit (30+ min) | 68 | $2,598 |
2020
| Return visit (30+ min) | 168 | $2,918 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 48 | $2,550 |
2019
| Return visit (30+ min) | 161 | $1,033 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $829 |
| Clinician who referred the patient to another clinician received a report from the clinician to whom the patient was referred | 48 | $0 |
| TOBACCO NON-USER | 91 | $0 |
| Advance Care Planning discussed and documented in the medical record, patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan (DEM) (GER, Pall Cr) | 71 | $0 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 94 | $0 |
| Pre-htn or htn doc, f/u indc | 49 | $0 |
| Patient screened for tobacco use and identified as a tobacco non-user | 87 | $0 |
2018
| Return visit (30+ min) | 329 | $2,830 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 76 | $2,547 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $368 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $68 |
Drugs they prescribed that Part D paid
$2,218,440
Pharmacies billed $2,218,440 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (38 of 9,331) in 2024. A higher opioid share than 9 in 10 peers; the typical cardiology clinician is at 0%.
6,886 generic and 2,432 brand-name prescriptions · $2,218,440 in drug cost · 28 antibiotic prescriptions to 23 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 375 | $349,985 | $933 |
| Entresto | 310 | $276,875 | $893 |
| Xarelto | 264 | $221,689 | $840 |
| Repatha Sureclick | 233 | $190,306 | $817 |
| Opsumit | 11 | $141,540 | $12,867 |
See all 111 drugs
| Eliquis | 375 | $349,985 | $933 |
| Entresto | 310 | $276,875 | $893 |
| Xarelto | 264 | $221,689 | $840 |
| Repatha Sureclick | 233 | $190,306 | $817 |
| Opsumit | 11 | $141,540 | $12,867 |
| Verquvo | 108 | $92,373 | $855 |
| Multaq | 69 | $88,153 | $1,278 |
| Farxiga | 102 | $69,260 | $679 |
| Ozempic | 51 | $55,946 | $1,097 |
| Vascepa | 120 | $53,035 | $442 |
| Jardiance | 52 | $46,354 | $891 |
| Trintellix | 56 | $33,588 | $600 |
| Brilinta | 49 | $30,941 | $631 |
| Mounjaro | 25 | $29,103 | $1,164 |
| Corlanor | 34 | $24,087 | $708 |
| Rybelsus | 16 | $20,310 | $1,269 |
| Edarbi | 45 | $16,641 | $370 |
| Linzess | 25 | $15,985 | $639 |
| Ranolazine Er | 147 | $14,459 | $98 |
| Edarbyclor | 44 | $11,663 | $265 |
| Praluent | 19 | $11,152 | $587 |
| Amiodarone | 181 | $7,641 | $42 |
| Icosapent Ethyl | 37 | $7,314 | $198 |
| Dexlansoprazole Dr | 32 | $7,016 | $219 |
| Nebivolol | 157 | $6,724 | $43 |
| Olmesartan-Hydrochlorothiazide | 161 | $5,829 | $36 |
| Prasugrel | 107 | $5,747 | $54 |
| Crestor | 12 | $5,437 | $453 |
| Atorvastatin | 579 | $4,987 | $9 |
| Metoprolol | 380 | $4,969 | $13 |
| Breo Ellipta | 11 | $4,267 | $388 |
| Clopidogrel | 393 | $3,718 | $9 |
| Plavix | 11 | $3,556 | $323 |
| Candesartan-Hydrochlorothiazid | 23 | $3,186 | $139 |
| Olmesartan-Amlodipine-Hctz | 27 | $2,752 | $102 |
| Rosuvastatin | 160 | $2,719 | $17 |
| Valsartan | 107 | $2,589 | $24 |
| Clonidine | 25 | $2,544 | $102 |
| Diltiazem 24hr Er (Cd) | 107 | $2,440 | $23 |
| Losartan | 176 | $2,223 | $13 |
| Digoxin | 129 | $2,183 | $17 |
| Olmesartan Medoxomil | 171 | $1,961 | $11 |
| Potassium Chloride | 92 | $1,879 | $20 |
| Toprol Xl | 16 | $1,863 | $116 |
| Metoprolol | 348 | $1,862 | $5 |
| Amlodipine Besylate | 369 | $1,777 | $5 |
| Synthroid | 17 | $1,726 | $102 |
| Candesartan Cilexetil | 28 | $1,640 | $59 |
| Butalbital-Acetaminophen-Caffe | 26 | $1,605 | $62 |
| Carvedilol | 258 | $1,549 | $6 |
| Propranolol | 81 | $1,501 | $19 |
| Spironolactone-Hctz | 40 | $1,489 | $37 |
| Fenofibrate | 23 | $1,424 | $62 |
| Clonidine | 161 | $1,278 | $8 |
| Valsartan-Hydrochlorothiazide | 56 | $1,270 | $23 |
| Diclofenac | 19 | $1,199 | $63 |
| Pantoprazole | 83 | $1,147 | $14 |
| Nitroglycerin | 117 | $1,131 | $10 |
| Losartan-Hydrochlorothiazide | 105 | $1,073 | $10 |
| Torsemide | 53 | $1,047 | $20 |
| Bumetanide | 27 | $932 | $35 |
| Lisinopril | 115 | $894 | $8 |
| Isosorbide Mononitrate Er | 60 | $781 | $13 |
| Hydralazine | 71 | $728 | $10 |
| Bisoprolol | 17 | $678 | $40 |
| Furosemide | 169 | $669 | $4 |
| Albuterol Sulfate Hfa | 21 | $636 | $30 |
| Nifedipine Er | 26 | $628 | $24 |
| Doxazosin Mesylate | 49 | $611 | $12 |
| Famotidine | 94 | $554 | $6 |
| Amlodipine-Valsartan | 11 | $489 | $44 |
| Gabapentin | 77 | $458 | $6 |
| Allopurinol | 35 | $456 | $13 |
| Diltiazem | 23 | $450 | $20 |
| Amlodipine Besylate-Benazepril | 13 | $424 | $33 |
| Escitalopram | 39 | $393 | $10 |
| Verapamil Er | 15 | $390 | $26 |
| Metformin | 56 | $368 | $7 |
| Sotalol | 50 | $368 | $7 |
| Irbesartan | 24 | $345 | $14 |
| Cartia Xt | 12 | $335 | $28 |
| Levothyroxine | 24 | $334 | $14 |
| Sertraline | 45 | $309 | $7 |
| Omeprazole | 29 | $306 | $11 |
| Pioglitazone | 20 | $290 | $15 |
| Esomeprazole Magnesium | 14 | $288 | $21 |
| Hydrochlorothiazide | 60 | $278 | $5 |
| Alprazolam | 39 | $274 | $7 |
| Ezetimibe | 12 | $260 | $22 |
| Terazosin | 16 | $245 | $15 |
| Tamsulosin | 28 | $244 | $9 |
| Simvastatin | 45 | $224 | $5 |
| Trazodone | 28 | $214 | $8 |
| Diazepam | 23 | $213 | $9 |
| Warfarin | 23 | $212 | $9 |
| Spironolactone | 72 | $203 | $3 |
| Ramipril | 29 | $180 | $6 |
| Tiadylt Er | 12 | $179 | $15 |
| Celecoxib | 13 | $175 | $13 |
| Megestrol Acetate | 11 | $169 | $15 |
| Zolpidem | 57 | $164 | $3 |
| Lorazepam | 24 | $160 | $7 |
| Glipizide | 14 | $155 | $11 |
| Lisinopril-Hydrochlorothiazide | 20 | $152 | $8 |
| Tramadol | 30 | $89 | $3 |
| Chlorthalidone | 12 | $83 | $7 |
| Meclizine | 13 | $80 | $6 |
| Atenolol | 30 | $49 | $2 |
| Pramipexole Dihydrochloride | 12 | $44 | $4 |
| Pravastatin | 13 | $21 | $2 |
| Clonazepam | 17 | $21 | $1 |
Year by year
| 2024 | 9,331 | 896 | 0% (38) | 26% | $2,218,440 |
| 2023 | 9,754 | 910 | 0% (32) | 27% | $2,347,093 |
| 2022 | 9,485 | 870 | 0% (29) | 29% | $2,136,663 |
| 2021 | 9,039 | 839 | 1% (43) | 32% | $1,990,388 |
| 2020 | 9,974 | 830 | 0% (40) | None | $1,895,393 |
| 2019 | 9,688 | 789 | 0% (24) | 33% | $1,822,366 |
| 2018 | 8,782 | 727 | 0% (17) | 35% | $1,603,442 |
| 2017 | 8,590 | 662 | 0% (25) | None | $1,392,640 |
| 2016 | 8,359 | 645 | 1% (41) | None | $1,244,847 |
| 2015 | 7,659 | 622 | 1% (56) | 38% | $901,988 |
| 2014 | 7,194 | 596 | 1% (41) | 40% | $854,687 |
| 2013 | 6,875 | 574 | 1% (40) | None | $665,085 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 122 drugs
| Eliquis | 386 | $385,073 | $998 |
| Xarelto | 287 | $271,520 | $946 |
| Entresto | 285 | $261,924 | $919 |
| Repatha Sureclick | 157 | $138,304 | $881 |
| Farxiga | 136 | $116,816 | $859 |
| Verquvo | 96 | $86,239 | $898 |
| Vascepa | 155 | $74,110 | $478 |
| Omeprazole-Sodium Bicarbonate | 13 | $70,994 | $5,461 |
| Mounjaro | 45 | $69,529 | $1,545 |
| Multaq | 53 | $65,274 | $1,232 |
| Corlanor | 62 | $57,608 | $929 |
| Jardiance | 52 | $51,360 | $988 |
| Trintellix | 81 | $51,100 | $631 |
| Rybelsus | 24 | $42,328 | $1,764 |
| Ozempic | 34 | $39,952 | $1,175 |
| Brilinta | 54 | $35,467 | $657 |
| Linzess | 36 | $24,844 | $690 |
| Bydureon Bcise | 24 | $22,597 | $942 |
| Ranolazine Er | 132 | $22,073 | $167 |
| Praluent | 34 | $20,131 | $592 |
| Pradaxa | 31 | $15,710 | $507 |
| Nebivolol | 179 | $15,066 | $84 |
| Edarbi | 42 | $14,192 | $338 |
| Edarbyclor | 53 | $13,772 | $260 |
| Dexlansoprazole Dr | 54 | $12,702 | $235 |
| Atorvastatin | 625 | $11,726 | $19 |
| Prasugrel | 114 | $10,725 | $94 |
| Advair Diskus | 20 | $9,891 | $495 |
| Metoprolol | 442 | $9,667 | $22 |
| Icosapent Ethyl | 26 | $9,523 | $366 |
| Amiodarone | 171 | $8,230 | $48 |
| Breo Ellipta | 18 | $7,695 | $428 |
| Rosuvastatin | 170 | $7,501 | $44 |
| Olmesartan-Hydrochlorothiazide | 137 | $7,117 | $52 |
| Belsomra | 11 | $7,020 | $638 |
| Janumet Xr | 12 | $6,996 | $583 |
| Livalo | 14 | $6,525 | $466 |
| Clopidogrel | 351 | $6,363 | $18 |
| Valsartan | 95 | $5,473 | $58 |
| Losartan | 206 | $5,123 | $25 |
| Amlodipine Besylate | 327 | $5,121 | $16 |
| Olmesartan Medoxomil | 145 | $5,038 | $35 |
| Bystolic | 11 | $4,766 | $433 |
| Metoprolol | 382 | $4,435 | $12 |
| Diltiazem 24hr Er (Cd) | 110 | $4,232 | $38 |
| Carvedilol | 240 | $4,228 | $18 |
| Digoxin | 141 | $4,124 | $29 |
| Candesartan-Hydrochlorothiazid | 19 | $3,511 | $185 |
| Candesartan Cilexetil | 31 | $3,446 | $111 |
| Losartan-Hydrochlorothiazide | 132 | $3,335 | $25 |
| Nifedipine Er | 47 | $3,242 | $69 |
| Clonidine | 204 | $3,192 | $16 |
| Nitroglycerin | 131 | $2,794 | $21 |
| Clonidine | 19 | $2,689 | $142 |
| Potassium Chloride | 106 | $2,286 | $22 |
| Lisinopril | 134 | $2,013 | $15 |
| Pacerone | 12 | $2,001 | $167 |
| Synthroid | 18 | $1,945 | $108 |
| Valsartan-Hydrochlorothiazide | 47 | $1,886 | $40 |
| Propranolol | 50 | $1,736 | $35 |
| Torsemide | 73 | $1,703 | $23 |
| Furosemide | 234 | $1,676 | $7 |
| Pantoprazole | 63 | $1,659 | $26 |
| Midodrine | 19 | $1,589 | $84 |
| Famotidine | 75 | $1,520 | $20 |
| Spironolactone-Hctz | 41 | $1,474 | $36 |
| Fenofibrate | 23 | $1,423 | $62 |
| Isosorbide Mononitrate Er | 43 | $1,389 | $32 |
| Bumetanide | 12 | $1,335 | $111 |
| Metformin | 80 | $1,269 | $16 |
| Propafenone | 16 | $1,228 | $77 |
| Olmesartan-Amlodipine-Hctz | 22 | $1,209 | $55 |
| Irbesartan | 21 | $1,201 | $57 |
| Spironolactone | 91 | $1,195 | $13 |
| Propranolol Hcl Er | 11 | $1,120 | $102 |
| Bisoprolol | 15 | $1,030 | $69 |
| Doxazosin Mesylate | 36 | $1,021 | $28 |
| Butalbital-Acetaminophen-Caffe | 20 | $977 | $49 |
| Hydralazine | 56 | $976 | $17 |
| Sotalol | 39 | $928 | $24 |
| Simvastatin | 65 | $917 | $14 |
| Tamsulosin | 23 | $880 | $38 |
| Albuterol Sulfate Hfa | 20 | $849 | $42 |
| Omeprazole | 36 | $845 | $23 |
| Zolpidem | 35 | $742 | $21 |
| Sertraline | 36 | $731 | $20 |
| Levothyroxine | 38 | $729 | $19 |
| Allopurinol | 30 | $714 | $24 |
| Trazodone | 39 | $704 | $18 |
| Diltiazem 24hr Er (Xr) | 17 | $672 | $40 |
| Hydrochlorothiazide | 58 | $630 | $11 |
| Gabapentin | 53 | $603 | $11 |
| Diltiazem | 17 | $572 | $34 |
| Diclofenac | 26 | $510 | $20 |
| Diltiazem 24hr Er | 14 | $482 | $34 |
| Escitalopram | 45 | $470 | $10 |
| Lisinopril-Hydrochlorothiazide | 20 | $452 | $23 |
| Atenolol | 26 | $451 | $17 |
| Alprazolam | 65 | $414 | $6 |
| Celecoxib | 19 | $393 | $21 |
| Ramipril | 27 | $382 | $14 |
| Irbesartan-Hydrochlorothiazide | 11 | $369 | $34 |
| Niacin Er | 14 | $369 | $26 |
| Memantine | 21 | $365 | $17 |
| Amlodipine Besylate-Benazepril | 13 | $338 | $26 |
| Pramipexole Dihydrochloride | 15 | $334 | $22 |
| Cartia Xt | 15 | $332 | $22 |
| Tramadol | 21 | $324 | $15 |
| Meclizine | 17 | $293 | $17 |
| Verapamil Er | 12 | $291 | $24 |
| Terazosin | 16 | $290 | $18 |
| Glipizide | 18 | $284 | $16 |
| Lorazepam | 17 | $274 | $16 |
| Pravastatin | 19 | $268 | $14 |
| Ibuprofen | 33 | $244 | $7 |
| Alendronate | 17 | $222 | $13 |
| Mirtazapine | 14 | $180 | $13 |
| Dutasteride | 13 | $155 | $12 |
| Warfarin | 12 | $143 | $12 |
| Diazepam | 20 | $126 | $6 |
| Alfuzosin Hcl Er | 13 | $116 | $9 |
| Azithromycin | 13 | $92 | $7 |
2022: 120 drugs
| Xarelto | 390 | $312,460 | $801 |
| Eliquis | 328 | $286,218 | $873 |
| Entresto | 288 | $234,230 | $813 |
| Repatha Sureclick | 188 | $134,027 | $713 |
| Farxiga | 110 | $87,917 | $799 |
| Vascepa | 128 | $60,178 | $470 |
| Trintellix | 98 | $59,991 | $612 |
| Multaq | 41 | $54,885 | $1,339 |
| Verquvo | 32 | $50,788 | $1,587 |
| Brilinta | 61 | $38,331 | $628 |
| Jardiance | 45 | $38,158 | $848 |
| Corlanor | 52 | $37,606 | $723 |
| Ranolazine Er | 118 | $27,851 | $236 |
| Dexilant | 54 | $25,498 | $472 |
| Pradaxa | 45 | $25,151 | $559 |
| Rybelsus | 11 | $23,966 | $2,179 |
| Prasugrel | 127 | $21,932 | $173 |
| Bydureon Bcise | 25 | $20,593 | $824 |
| Linzess | 32 | $19,988 | $625 |
| Edarbi | 69 | $18,303 | $265 |
| Praluent | 33 | $16,477 | $499 |
| Bystolic | 43 | $16,043 | $373 |
| Ozempic | 11 | $15,093 | $1,372 |
| Edarbyclor | 43 | $13,688 | $318 |
| Nebivolol | 160 | $13,324 | $83 |
| Ranexa | 14 | $13,210 | $944 |
| Trulicity | 11 | $10,438 | $949 |
| Rosuvastatin | 171 | $9,290 | $54 |
| Olmesartan-Hydrochlorothiazide | 127 | $8,633 | $68 |
| Advair Diskus | 18 | $7,700 | $428 |
| Breo Ellipta | 18 | $7,447 | $414 |
| Atorvastatin | 550 | $7,260 | $13 |
| Metoprolol | 412 | $7,209 | $17 |
| Livalo | 11 | $6,732 | $612 |
| Janumet Xr | 12 | $6,634 | $553 |
| Belsomra | 11 | $5,471 | $497 |
| Clonidine | 24 | $5,032 | $210 |
| Valsartan | 44 | $5,022 | $114 |
| Amiodarone | 134 | $4,984 | $37 |
| Amitiza | 12 | $4,789 | $399 |
| Dexlansoprazole Dr | 15 | $4,769 | $318 |
| Clopidogrel | 332 | $4,613 | $14 |
| Olmesartan Medoxomil | 116 | $4,342 | $37 |
| Icosapent Ethyl | 16 | $4,201 | $263 |
| Olmesartan-Amlodipine-Hctz | 33 | $3,795 | $115 |
| Diltiazem 24hr Er (Cd) | 113 | $3,632 | $32 |
| Digoxin | 113 | $3,530 | $31 |
| Nitroglycerin | 155 | $3,524 | $23 |
| Candesartan Cilexetil | 33 | $3,456 | $105 |
| Candesartan-Hydrochlorothiazid | 15 | $3,228 | $215 |
| Metoprolol | 348 | $3,002 | $9 |
| Famotidine | 74 | $2,881 | $39 |
| Losartan-Hydrochlorothiazide | 111 | $2,562 | $23 |
| Carvedilol | 220 | $2,488 | $11 |
| Losartan | 198 | $2,374 | $12 |
| Potassium Chloride | 100 | $2,250 | $23 |
| Clonidine | 170 | $2,244 | $13 |
| Amlodipine Besylate | 343 | $2,118 | $6 |
| Pregabalin | 25 | $2,113 | $85 |
| Nifedipine Er | 48 | $1,972 | $41 |
| Fenofibrate | 15 | $1,828 | $122 |
| Synthroid | 13 | $1,801 | $139 |
| Bumetanide | 14 | $1,700 | $121 |
| Valsartan-Hydrochlorothiazide | 31 | $1,463 | $47 |
| Propafenone | 14 | $1,293 | $92 |
| Torsemide | 105 | $1,264 | $12 |
| Memantine | 26 | $1,173 | $45 |
| Isosorbide Mononitrate Er | 65 | $1,132 | $17 |
| Lisinopril | 158 | $1,116 | $7 |
| Furosemide | 206 | $1,081 | $5 |
| Spironolactone-Hctz | 22 | $1,022 | $46 |
| Omeprazole | 57 | $1,010 | $18 |
| Irbesartan | 24 | $985 | $41 |
| Oxybutynin Chloride Er | 25 | $966 | $39 |
| Levothyroxine | 54 | $934 | $17 |
| Metformin | 79 | $797 | $10 |
| Diltiazem 24hr Er | 30 | $733 | $24 |
| Propranolol | 34 | $700 | $21 |
| Pantoprazole | 54 | $641 | $12 |
| Trazodone | 54 | $640 | $12 |
| Digox | 25 | $616 | $25 |
| Gabapentin | 62 | $612 | $10 |
| Midodrine | 14 | $598 | $43 |
| Diclofenac | 31 | $587 | $19 |
| Irbesartan-Hydrochlorothiazide | 16 | $529 | $33 |
| Hydralazine | 35 | $516 | $15 |
| Spironolactone | 75 | $514 | $7 |
| Doxazosin Mesylate | 27 | $500 | $19 |
| Zolpidem | 50 | $491 | $10 |
| Mirtazapine | 19 | $490 | $26 |
| Escitalopram | 51 | $475 | $9 |
| Tamsulosin | 14 | $466 | $33 |
| Sotalol | 22 | $443 | $20 |
| Allopurinol | 33 | $442 | $13 |
| Terazosin | 25 | $430 | $17 |
| Alprazolam | 67 | $430 | $6 |
| Amlodipine Besylate-Benazepril | 15 | $428 | $29 |
| Celecoxib | 24 | $423 | $18 |
| Simvastatin | 55 | $405 | $7 |
| Sertraline | 50 | $366 | $7 |
| Ramipril | 32 | $362 | $11 |
| Hydrochlorothiazide | 42 | $341 | $8 |
| Pravastatin | 19 | $332 | $17 |
| Cartia Xt | 17 | $328 | $19 |
| Lisinopril-Hydrochlorothiazide | 27 | $292 | $11 |
| Niacin Er | 16 | $272 | $17 |
| Verapamil Er | 13 | $262 | $20 |
| Lorazepam | 30 | $259 | $9 |
| Fluticasone Propionate | 20 | $252 | $13 |
| Atenolol | 28 | $247 | $9 |
| Ibuprofen | 31 | $232 | $7 |
| Glipizide | 23 | $231 | $10 |
| Diltiazem | 13 | $206 | $16 |
| Quetiapine | 13 | $111 | $9 |
| Diazepam | 13 | $73 | $6 |
| Chlorhexidine Gluconate | 13 | $60 | $5 |
| Dutasteride | 11 | $49 | $4 |
| Alcohol Prep Pads | 17 | $38 | $2 |
| Alfuzosin Hcl Er | 12 | $35 | $3 |
| Tramadol | 15 | $33 | $2 |
2021: 121 drugs
| Xarelto | 343 | $270,719 | $789 |
| Eliquis | 320 | $253,811 | $793 |
| Entresto | 261 | $185,304 | $710 |
| Letairis | 12 | $144,468 | $12,039 |
| Repatha Sureclick | 184 | $105,858 | $575 |
| Vascepa | 163 | $68,824 | $422 |
| Trintellix | 114 | $68,003 | $597 |
| Bystolic | 217 | $66,508 | $306 |
| Farxiga | 83 | $65,310 | $787 |
| Multaq | 54 | $60,257 | $1,116 |
| Corlanor | 76 | $44,492 | $585 |
| Brilinta | 82 | $43,949 | $536 |
| Xifaxan | 13 | $37,646 | $2,896 |
| Dexilant | 61 | $31,048 | $509 |
| Pradaxa | 44 | $30,111 | $684 |
| Rybelsus | 18 | $29,981 | $1,666 |
| Trulicity | 29 | $27,889 | $962 |
| Jardiance | 34 | $26,404 | $777 |
| Edarbyclor | 77 | $22,560 | $293 |
| Praluent | 26 | $18,867 | $726 |
| Ranexa | 24 | $18,624 | $776 |
| Edarbi | 46 | $18,202 | $396 |
| Ranolazine Er | 84 | $16,296 | $194 |
| Linzess | 24 | $11,883 | $495 |
| Prasugrel | 82 | $11,749 | $143 |
| Amitiza | 22 | $10,191 | $463 |
| Symbicort | 16 | $9,401 | $588 |
| Anoro Ellipta | 19 | $8,401 | $442 |
| Amiodarone | 159 | $8,261 | $52 |
| Creon | 14 | $8,003 | $572 |
| Welchol | 11 | $7,207 | $655 |
| Atorvastatin | 476 | $6,191 | $13 |
| Rosuvastatin | 151 | $5,985 | $40 |
| Olmesartan Medoxomil | 113 | $5,982 | $53 |
| Metoprolol | 348 | $5,721 | $16 |
| Olmesartan-Amlodipine-Hctz | 19 | $5,451 | $287 |
| Olmesartan-Hydrochlorothiazide | 96 | $5,139 | $54 |
| Digoxin | 102 | $3,788 | $37 |
| Valsartan | 54 | $3,556 | $66 |
| Nitroglycerin | 127 | $3,473 | $27 |
| Clonidine | 13 | $2,905 | $223 |
| Clopidogrel | 298 | $2,812 | $9 |
| Pacerone | 12 | $2,735 | $228 |
| Losartan | 215 | $2,671 | $12 |
| Losartan-Hydrochlorothiazide | 115 | $2,558 | $22 |
| Diltiazem 24hr Er (Cd) | 73 | $2,531 | $35 |
| Candesartan Cilexetil | 29 | $2,439 | $84 |
| Metoprolol | 316 | $2,394 | $8 |
| Amlodipine Besylate | 404 | $2,313 | $6 |
| Carvedilol | 241 | $2,186 | $9 |
| Potassium Chloride | 117 | $2,042 | $17 |
| Irbesartan | 54 | $1,861 | $34 |
| Propranolol | 43 | $1,781 | $41 |
| Nebivolol | 20 | $1,757 | $88 |
| Synthroid | 12 | $1,523 | $127 |
| Clonidine | 117 | $1,502 | $13 |
| Ezetimibe | 12 | $1,446 | $121 |
| Propafenone | 17 | $1,429 | $84 |
| Tresiba Flextouch U-100 | 13 | $1,395 | $107 |
| Lisinopril | 170 | $1,346 | $8 |
| Pregabalin | 16 | $1,128 | $70 |
| Bumetanide | 13 | $1,076 | $83 |
| Fenofibrate | 12 | $1,053 | $88 |
| Digox | 40 | $1,048 | $26 |
| Propranolol Hcl Er | 12 | $1,017 | $85 |
| Torsemide | 81 | $994 | $12 |
| Lidocaine | 12 | $990 | $82 |
| Nifedipine Er | 35 | $872 | $25 |
| Spironolactone | 118 | $862 | $7 |
| Levothyroxine | 47 | $832 | $18 |
| Omeprazole | 58 | $769 | $13 |
| Terazosin | 43 | $744 | $17 |
| Famotidine | 53 | $734 | $14 |
| Furosemide | 184 | $698 | $4 |
| Lansoprazole | 12 | $631 | $53 |
| Diltiazem 24hr Er | 26 | $623 | $24 |
| Valsartan-Hydrochlorothiazide | 30 | $581 | $19 |
| Cartia Xt | 18 | $576 | $32 |
| Ramipril | 56 | $569 | $10 |
| Trazodone | 62 | $556 | $9 |
| Spironolactone-Hctz | 15 | $555 | $37 |
| Tamsulosin | 23 | $544 | $24 |
| Pantoprazole | 45 | $493 | $11 |
| Isosorbide Mononitrate Er | 49 | $472 | $10 |
| Amlodipine Besylate-Benazepril | 16 | $466 | $29 |
| Alprazolam | 49 | $459 | $9 |
| Sotalol | 23 | $451 | $20 |
| Gabapentin | 39 | $438 | $11 |
| Memantine | 12 | $409 | $34 |
| Doxazosin Mesylate | 21 | $395 | $19 |
| Celecoxib | 23 | $374 | $16 |
| Allopurinol | 49 | $368 | $8 |
| Irbesartan-Hydrochlorothiazide | 20 | $352 | $18 |
| Hydrochlorothiazide | 38 | $346 | $9 |
| Meclizine | 30 | $314 | $10 |
| Hydralazine | 18 | $310 | $17 |
| Diclofenac | 20 | $284 | $14 |
| Escitalopram | 40 | $259 | $6 |
| Simvastatin | 48 | $256 | $5 |
| Diltiazem | 14 | $239 | $17 |
| Quetiapine | 27 | $234 | $9 |
| Warfarin | 14 | $232 | $17 |
| Sertraline | 55 | $219 | $4 |
| Lisinopril-Hydrochlorothiazide | 33 | $212 | $6 |
| Amoxicillin-Clavulanate Potass | 14 | $203 | $14 |
| Atenolol | 29 | $197 | $7 |
| Niacin Er | 14 | $185 | $13 |
| Tramadol | 26 | $180 | $7 |
| Zolpidem | 27 | $174 | $6 |
| Meloxicam | 19 | $162 | $9 |
| Lorazepam | 26 | $160 | $6 |
| Metformin | 41 | $153 | $4 |
| Finasteride | 15 | $151 | $10 |
| Diazepam | 18 | $136 | $8 |
| Glipizide | 20 | $94 | $5 |
| Buspirone | 14 | $90 | $6 |
| Dicyclomine | 13 | $69 | $5 |
| Alfuzosin Hcl Er | 13 | $63 | $5 |
| Dutasteride | 12 | $55 | $5 |
| Pramipexole Dihydrochloride | 12 | $53 | $4 |
| Alcohol Prep Pads | 14 | $32 | $2 |
2020: 131 drugs
| Xarelto | 334 | $236,337 | $708 |
| Eliquis | 307 | $215,323 | $701 |
| Entresto | 279 | $182,033 | $652 |
| Letairis | 13 | $128,163 | $9,859 |
| Repatha Sureclick | 173 | $89,181 | $515 |
| Vascepa | 181 | $77,275 | $427 |
| Multaq | 69 | $75,031 | $1,087 |
| Bystolic | 253 | $70,894 | $280 |
| Brilinta | 128 | $66,248 | $518 |
| Trintellix | 124 | $63,075 | $509 |
| Corlanor | 77 | $41,176 | $535 |
| Jardiance | 57 | $39,403 | $691 |
| Xifaxan | 14 | $37,378 | $2,670 |
| Pradaxa | 64 | $34,528 | $540 |
| Dexilant | 60 | $33,724 | $562 |
| Farxiga | 36 | $29,558 | $821 |
| Ranolazine Er | 137 | $25,637 | $187 |
| Trulicity | 12 | $19,722 | $1,643 |
| Ranexa | 32 | $18,812 | $588 |
| Edarbi | 47 | $15,911 | $339 |
| Edarbyclor | 56 | $15,317 | $274 |
| Praluent | 18 | $14,623 | $812 |
| Amitiza | 28 | $13,825 | $494 |
| Linzess | 27 | $13,351 | $494 |
| Amiodarone | 184 | $10,372 | $56 |
| Crestor | 13 | $9,289 | $715 |
| Losartan-Hydrochlorothiazide | 109 | $9,035 | $83 |
| Rosuvastatin | 154 | $7,826 | $51 |
| Welchol | 12 | $7,755 | $646 |
| Atorvastatin | 528 | $7,421 | $14 |
| Olmesartan Medoxomil | 142 | $6,729 | $47 |
| Metoprolol | 358 | $6,171 | $17 |
| Digoxin | 125 | $5,715 | $46 |
| Prasugrel | 51 | $5,306 | $104 |
| Anoro Ellipta | 12 | $5,061 | $422 |
| Nitroglycerin | 179 | $4,802 | $27 |
| Candesartan Cilexetil | 40 | $4,744 | $119 |
| Myrbetriq | 11 | $4,537 | $412 |
| Pacerone | 14 | $4,248 | $303 |
| Potassium Chloride | 172 | $3,688 | $21 |
| Climara Pro | 13 | $3,532 | $272 |
| Nexium | 13 | $3,465 | $267 |
| Clopidogrel | 305 | $3,422 | $11 |
| Olmesartan-Hydrochlorothiazide | 63 | $3,391 | $54 |
| Diltiazem 24hr Er (Cd) | 115 | $2,881 | $25 |
| Candesartan-Hydrochlorothiazid | 11 | $2,802 | $255 |
| Pregabalin | 48 | $2,557 | $53 |
| Losartan | 232 | $2,547 | $11 |
| Clonidine | 15 | $2,487 | $166 |
| Valsartan | 41 | $2,408 | $59 |
| Olmesartan-Amlodipine-Hctz | 11 | $2,221 | $202 |
| Irbesartan | 63 | $2,156 | $34 |
| Amlodipine Besylate | 374 | $2,100 | $6 |
| Esomeprazole Magnesium | 11 | $2,070 | $188 |
| Clonidine | 162 | $1,989 | $12 |
| Propranolol Hcl Er | 15 | $1,904 | $127 |
| Metoprolol | 324 | $1,900 | $6 |
| Synthroid | 20 | $1,885 | $94 |
| Carvedilol | 264 | $1,860 | $7 |
| Ezetimibe | 13 | $1,287 | $99 |
| Propafenone | 28 | $1,190 | $43 |
| Tresiba Flextouch U-100 | 11 | $1,180 | $107 |
| Irbesartan-Hydrochlorothiazide | 27 | $1,149 | $43 |
| Midodrine | 11 | $1,020 | $93 |
| Lisinopril | 155 | $980 | $6 |
| Nifedipine Er | 28 | $964 | $34 |
| Digox | 48 | $959 | $20 |
| Fenofibrate | 26 | $956 | $37 |
| Fenofibric Acid | 12 | $939 | $78 |
| Furosemide | 293 | $904 | $3 |
| Hydralazine | 63 | $884 | $14 |
| Isosorbide Mononitrate Er | 74 | $840 | $11 |
| Butalbital-Acetaminophen-Caffe | 13 | $812 | $62 |
| Cartia Xt | 24 | $807 | $34 |
| Valsartan-Hydrochlorothiazide | 18 | $794 | $44 |
| Bisoprolol | 15 | $791 | $53 |
| Spironolactone | 124 | $789 | $6 |
| Levothyroxine | 53 | $737 | $14 |
| Alprazolam | 80 | $714 | $9 |
| Famotidine | 39 | $663 | $17 |
| Propranolol | 22 | $653 | $30 |
| Hydrochlorothiazide | 81 | $616 | $8 |
| Torsemide | 87 | $615 | $7 |
| Amlodipine Besylate-Benazepril | 11 | $612 | $56 |
| Dutasteride | 12 | $564 | $47 |
| Doxazosin Mesylate | 29 | $559 | $19 |
| Trazodone | 50 | $551 | $11 |
| Omeprazole | 45 | $538 | $12 |
| Ramipril | 65 | $495 | $8 |
| Tamsulosin | 16 | $481 | $30 |
| Diltiazem | 32 | $454 | $14 |
| Terazosin | 23 | $439 | $19 |
| Pantoprazole | 48 | $410 | $9 |
| Memantine | 12 | $402 | $33 |
| Atenolol | 48 | $402 | $8 |
| Hydrocodone-Acetaminophen | 12 | $401 | $33 |
| Meclizine | 30 | $371 | $12 |
| Metformin | 95 | $363 | $4 |
| Allopurinol | 61 | $355 | $6 |
| Bumetanide | 11 | $349 | $32 |
| Sotalol | 26 | $348 | $13 |
| Isosorbide Mononitrate | 11 | $346 | $31 |
| Escitalopram | 59 | $323 | $5 |
| Gabapentin | 30 | $321 | $11 |
| Pravastatin | 14 | $312 | $22 |
| Warfarin | 11 | $304 | $28 |
| Divalproex | 12 | $303 | $25 |
| Primidone | 11 | $299 | $27 |
| Oxybutynin Chloride | 21 | $289 | $14 |
| Simvastatin | 72 | $284 | $4 |
| Amoxicillin-Clavulanate Potass | 12 | $275 | $23 |
| Niacin Er | 12 | $270 | $23 |
| Finasteride | 32 | $247 | $8 |
| Dextroamphetamine-Amphetamine | 11 | $219 | $20 |
| Sertraline | 46 | $212 | $5 |
| Zolpidem | 32 | $181 | $6 |
| Benazepril | 16 | $173 | $11 |
| Quetiapine | 16 | $170 | $11 |
| Montelukast | 21 | $157 | $7 |
| Diazepam | 29 | $155 | $5 |
| Meloxicam | 35 | $152 | $4 |
| Lisinopril-Hydrochlorothiazide | 28 | $117 | $4 |
| Glipizide | 15 | $113 | $8 |
| Azithromycin | 11 | $108 | $10 |
| Alendronate | 13 | $82 | $6 |
| Buspirone | 18 | $76 | $4 |
| Triamcinolone Acetonide | 13 | $69 | $5 |
| Lorazepam | 19 | $67 | $4 |
| Methimazole | 13 | $63 | $5 |
| Alfuzosin Hcl Er | 12 | $49 | $4 |
| Tramadol | 18 | $43 | $2 |
2019: 127 drugs
| Eliquis | 283 | $188,082 | $665 |
| Entresto | 340 | $188,006 | $553 |
| Xarelto | 277 | $179,517 | $648 |
| Letairis | 13 | $120,975 | $9,306 |
| Repatha Sureclick | 136 | $117,870 | $867 |
| Brilinta | 206 | $98,140 | $476 |
| Multaq | 76 | $71,563 | $942 |
| Vascepa | 157 | $56,922 | $363 |
| Trintellix | 128 | $51,219 | $400 |
| Jardiance | 72 | $46,728 | $649 |
| Ranexa | 65 | $43,684 | $672 |
| Pradaxa | 70 | $42,901 | $613 |
| Bystolic | 163 | $40,881 | $251 |
| Corlanor | 76 | $34,197 | $450 |
| Dexilant | 78 | $33,124 | $425 |
| Xifaxan | 12 | $29,667 | $2,472 |
| Ranolazine Er | 104 | $28,453 | $274 |
| Trulicity | 22 | $19,702 | $896 |
| Uloric | 34 | $17,406 | $512 |
| Amiodarone | 211 | $14,390 | $68 |
| Lyrica | 29 | $13,930 | $480 |
| Edarbyclor | 47 | $11,255 | $239 |
| Amitiza | 28 | $10,313 | $368 |
| Edarbi | 32 | $10,114 | $316 |
| Rosuvastatin | 167 | $9,002 | $54 |
| Atorvastatin | 524 | $8,754 | $17 |
| Metoprolol | 378 | $8,747 | $23 |
| Linzess | 18 | $7,935 | $441 |
| Welchol | 12 | $7,670 | $639 |
| Breo Ellipta | 20 | $7,546 | $377 |
| Janumet Xr | 13 | $6,278 | $483 |
| Olmesartan Medoxomil | 58 | $6,063 | $105 |
| Olmesartan-Hydrochlorothiazide | 76 | $5,937 | $78 |
| Prasugrel | 51 | $5,903 | $116 |
| Candesartan-Hydrochlorothiazid | 35 | $5,496 | $157 |
| Vesicare | 13 | $5,339 | $411 |
| Benicar Hct | 14 | $5,037 | $360 |
| Tekturna Hct | 12 | $4,955 | $413 |
| Febuxostat | 13 | $4,633 | $356 |
| Candesartan Cilexetil | 49 | $4,537 | $93 |
| Digoxin | 95 | $4,293 | $45 |
| Potassium Chloride | 188 | $4,285 | $23 |
| Nitroglycerin | 158 | $3,930 | $25 |
| Diltiazem 24hr Er (Cd) | 103 | $3,761 | $37 |
| Clonidine | 26 | $3,544 | $136 |
| Olmesartan-Amlodipine-Hctz | 20 | $3,413 | $171 |
| Clopidogrel | 241 | $3,001 | $12 |
| Carvedilol | 313 | $2,811 | $9 |
| Triazolam | 14 | $2,566 | $183 |
| Esomeprazole Magnesium | 22 | $2,518 | $114 |
| Metoprolol | 372 | $2,467 | $7 |
| Losartan | 261 | $2,322 | $9 |
| Amlodipine Besylate | 370 | $2,249 | $6 |
| Amlodipine-Olmesartan | 14 | $2,206 | $158 |
| Irbesartan | 55 | $2,036 | $37 |
| Propranolol Hcl Er | 16 | $1,962 | $123 |
| Isosorbide Dinitrate | 12 | $1,900 | $158 |
| Valsartan | 35 | $1,716 | $49 |
| Clonidine | 140 | $1,710 | $12 |
| Ezetimibe | 11 | $1,549 | $141 |
| Propafenone | 29 | $1,511 | $52 |
| Yosprala | 16 | $1,471 | $92 |
| Midodrine | 14 | $1,461 | $104 |
| Digox | 55 | $1,443 | $26 |
| Fenofibric Acid | 13 | $1,401 | $108 |
| Eplerenone | 13 | $1,377 | $106 |
| Losartan-Hydrochlorothiazide | 137 | $1,347 | $10 |
| Isosorbide Mononitrate Er | 64 | $1,314 | $21 |
| Memantine | 37 | $1,268 | $34 |
| Irbesartan-Hydrochlorothiazide | 35 | $1,264 | $36 |
| Furosemide | 313 | $1,137 | $4 |
| Synthroid | 16 | $1,051 | $66 |
| Fenofibrate | 25 | $1,044 | $42 |
| Levothyroxine | 49 | $996 | $20 |
| Digitek | 19 | $974 | $51 |
| Lisinopril | 100 | $956 | $10 |
| Cartia Xt | 29 | $920 | $32 |
| Trazodone | 48 | $884 | $18 |
| Doxazosin Mesylate | 28 | $850 | $30 |
| Diltiazem | 22 | $848 | $39 |
| Telmisartan | 11 | $789 | $72 |
| Nifedipine Er | 20 | $786 | $39 |
| Toprol Xl | 15 | $765 | $51 |
| Spironolactone-Hctz | 12 | $752 | $63 |
| Amlodipine Besylate-Benazepril | 14 | $743 | $53 |
| Spironolactone | 122 | $716 | $6 |
| Tamsulosin | 12 | $659 | $55 |
| Pantoprazole | 59 | $656 | $11 |
| Hydralazine | 56 | $621 | $11 |
| Omeprazole | 52 | $615 | $12 |
| Diltiazem 24hr Er | 20 | $611 | $31 |
| Allopurinol | 56 | $601 | $11 |
| Ramipril | 59 | $600 | $10 |
| Alprazolam | 78 | $542 | $7 |
| Metformin | 86 | $537 | $6 |
| Niacin Er | 12 | $507 | $42 |
| Escitalopram | 46 | $507 | $11 |
| Gabapentin | 19 | $502 | $26 |
| Hydrochlorothiazide | 66 | $495 | $7 |
| Simvastatin | 73 | $465 | $6 |
| Atenolol | 50 | $426 | $9 |
| Benazepril | 20 | $385 | $19 |
| Celecoxib | 12 | $347 | $29 |
| Primidone | 11 | $335 | $30 |
| Zolpidem | 42 | $312 | $7 |
| Sotalol | 15 | $307 | $20 |
| Pravastatin | 15 | $301 | $20 |
| Montelukast | 18 | $300 | $17 |
| Famotidine | 20 | $296 | $15 |
| Isosorbide Mononitrate | 22 | $294 | $13 |
| Hydrocodone-Acetaminophen | 13 | $267 | $21 |
| Verapamil Er | 13 | $220 | $17 |
| Diazepam | 29 | $188 | $6 |
| Meclizine | 19 | $176 | $9 |
| Warfarin | 11 | $171 | $16 |
| Easy Touch Pen Needle | 12 | $170 | $14 |
| Paroxetine | 12 | $165 | $14 |
| Ranitidine | 20 | $151 | $8 |
| Lorazepam | 17 | $139 | $8 |
| Amoxicillin-Clavulanate Potass | 11 | $131 | $12 |
| Sertraline | 23 | $122 | $5 |
| Alendronate | 17 | $92 | $5 |
| Meloxicam | 26 | $91 | $3 |
| Oxybutynin Chloride | 12 | $88 | $7 |
| Glipizide | 18 | $82 | $5 |
| Finasteride | 19 | $77 | $4 |
| Methimazole | 12 | $54 | $5 |
2018: 135 drugs
| Eliquis | 234 | $147,922 | $632 |
| Letairis | 16 | $144,067 | $9,004 |
| Ranexa | 224 | $132,382 | $591 |
| Repatha Sureclick | 105 | $118,904 | $1,132 |
| Xarelto | 219 | $116,404 | $532 |
| Entresto | 192 | $94,199 | $491 |
| Brilinta | 148 | $68,959 | $466 |
| Multaq | 74 | $59,457 | $803 |
| Uloric | 99 | $50,148 | $507 |
| Pradaxa | 101 | $48,825 | $483 |
| Vascepa | 91 | $35,284 | $388 |
| Bystolic | 148 | $32,257 | $218 |
| Jardiance | 43 | $29,128 | $677 |
| Dexilant | 77 | $28,670 | $372 |
| Lyrica | 63 | $28,267 | $449 |
| Corlanor | 50 | $22,778 | $456 |
| Prasugrel | 106 | $16,427 | $155 |
| Trintellix | 40 | $15,216 | $380 |
| Praluent | 12 | $14,406 | $1,201 |
| Zontivity | 34 | $10,895 | $320 |
| Amitiza | 22 | $9,811 | $446 |
| Crestor | 22 | $8,365 | $380 |
| Edarbyclor | 39 | $8,310 | $213 |
| Amiodarone | 167 | $8,004 | $48 |
| Coreg | 16 | $7,907 | $494 |
| Advair Diskus | 13 | $7,819 | $601 |
| Rosuvastatin | 118 | $7,594 | $64 |
| Welchol | 12 | $7,305 | $609 |
| Metoprolol | 255 | $7,176 | $28 |
| Atorvastatin | 474 | $7,029 | $15 |
| Olmesartan-Hydrochlorothiazide | 70 | $6,757 | $97 |
| Effient | 15 | $6,587 | $439 |
| Tekturna Hct | 17 | $5,417 | $319 |
| Horizant | 13 | $5,043 | $388 |
| Diltiazem 24hr Er (Cd) | 147 | $5,029 | $34 |
| Tekturna | 13 | $4,832 | $372 |
| Potassium Chloride | 196 | $4,615 | $24 |
| Breo Ellipta | 13 | $4,311 | $332 |
| Yosprala | 15 | $4,299 | $287 |
| Esomeprazole Magnesium | 31 | $4,238 | $137 |
| Exforge | 12 | $3,865 | $322 |
| Edarbi | 16 | $3,771 | $236 |
| Nexium | 12 | $3,748 | $312 |
| Digoxin | 59 | $3,575 | $61 |
| Valsartan | 137 | $3,560 | $26 |
| Omega-3 Acid Ethyl Esters | 22 | $2,886 | $131 |
| Nitroglycerin | 98 | $2,717 | $28 |
| Celecoxib | 16 | $2,681 | $168 |
| Olmesartan-Amlodipine-Hctz | 11 | $2,577 | $234 |
| Propranolol Hcl Er | 19 | $2,528 | $133 |
| Trilipix | 12 | $2,460 | $205 |
| Olmesartan Medoxomil | 32 | $2,428 | $76 |
| Candesartan-Hydrochlorothiazid | 15 | $2,309 | $154 |
| Clopidogrel | 187 | $2,243 | $12 |
| Candesartan Cilexetil | 20 | $2,236 | $112 |
| Clonidine | 11 | $2,221 | $202 |
| Metoprolol | 314 | $1,911 | $6 |
| Propafenone | 48 | $1,870 | $39 |
| Coumadin | 15 | $1,857 | $124 |
| Isosorbide Dinitrate | 11 | $1,835 | $167 |
| Carvedilol | 255 | $1,711 | $7 |
| Valsartan-Hydrochlorothiazide | 86 | $1,706 | $20 |
| Levothyroxine | 60 | $1,659 | $28 |
| Digox | 62 | $1,557 | $25 |
| Amlodipine Besylate | 282 | $1,511 | $5 |
| Isosorbide Mononitrate Er | 81 | $1,375 | $17 |
| Voltaren | 25 | $1,372 | $55 |
| Eplerenone | 12 | $1,365 | $114 |
| Memantine | 31 | $1,335 | $43 |
| Losartan | 149 | $1,297 | $9 |
| Clonidine | 138 | $1,288 | $9 |
| Triazolam | 12 | $1,236 | $103 |
| Midodrine | 15 | $1,172 | $78 |
| Butalbital-Acetaminophen-Caffe | 23 | $1,103 | $48 |
| Digitek | 22 | $1,100 | $50 |
| Furosemide | 269 | $1,080 | $4 |
| Propranolol | 16 | $1,065 | $67 |
| Flecainide Acetate | 19 | $1,013 | $53 |
| Cartia Xt | 26 | $953 | $37 |
| Losartan-Hydrochlorothiazide | 105 | $937 | $9 |
| Lisinopril | 105 | $906 | $9 |
| Fenofibrate | 25 | $833 | $33 |
| Tamsulosin | 24 | $787 | $33 |
| Chlorthalidone | 15 | $770 | $51 |
| Amlodipine-Valsartan | 12 | $767 | $64 |
| Niacin Er | 12 | $764 | $64 |
| Bisoprolol | 14 | $747 | $53 |
| Irbesartan | 28 | $714 | $25 |
| Gabapentin | 31 | $678 | $22 |
| Ramipril | 70 | $677 | $10 |
| Spironolactone | 86 | $662 | $8 |
| Sotalol | 23 | $582 | $25 |
| Alprazolam | 81 | $567 | $7 |
| Nifedipine Er | 27 | $564 | $21 |
| Fenofibrate | 11 | $553 | $50 |
| Simvastatin | 101 | $541 | $5 |
| Atenolol | 59 | $479 | $8 |
| Zolpidem | 45 | $473 | $11 |
| Diltiazem | 16 | $462 | $29 |
| Omeprazole | 44 | $459 | $10 |
| Trazodone | 29 | $443 | $15 |
| Metformin | 100 | $442 | $4 |
| Megestrol Acetate | 13 | $430 | $33 |
| Hydrochlorothiazide | 68 | $425 | $6 |
| Famotidine | 29 | $419 | $14 |
| Escitalopram | 51 | $409 | $8 |
| Toprol Xl | 11 | $403 | $37 |
| Pravastatin | 15 | $355 | $24 |
| Pantoprazole | 34 | $353 | $10 |
| Hydrocodone-Acetaminophen | 12 | $349 | $29 |
| Benazepril-Hydrochlorothiazide | 12 | $349 | $29 |
| Enalapril Maleate | 17 | $345 | $20 |
| Klor-Con 10 | 14 | $322 | $23 |
| Doxazosin Mesylate | 14 | $304 | $22 |
| Lorazepam | 65 | $291 | $4 |
| Meclizine | 24 | $289 | $12 |
| Terazosin | 13 | $270 | $21 |
| Irbesartan-Hydrochlorothiazide | 15 | $261 | $17 |
| Sertraline | 37 | $239 | $6 |
| Pioglitazone | 14 | $223 | $16 |
| Warfarin | 12 | $220 | $18 |
| Hydralazine | 11 | $202 | $18 |
| Isosorbide Mononitrate | 16 | $188 | $12 |
| Allopurinol | 25 | $175 | $7 |
| Diazepam | 25 | $160 | $6 |
| Ranitidine | 18 | $155 | $9 |
| Benazepril | 19 | $152 | $8 |
| Buspirone | 14 | $141 | $10 |
| Oxybutynin Chloride | 12 | $130 | $11 |
| Meloxicam | 26 | $100 | $4 |
| Paroxetine | 12 | $79 | $7 |
| Finasteride | 16 | $72 | $4 |
| Methimazole | 13 | $72 | $6 |
| Alendronate | 19 | $59 | $3 |
| Glipizide | 14 | $44 | $3 |
2017: 133 drugs
| Ranexa | 277 | $149,952 | $541 |
| Eliquis | 219 | $111,525 | $509 |
| Letairis | 12 | $104,140 | $8,678 |
| Repatha Sureclick | 76 | $86,450 | $1,138 |
| Entresto | 169 | $80,770 | $478 |
| Uloric | 132 | $63,551 | $481 |
| Effient | 110 | $54,632 | $497 |
| Pradaxa | 98 | $49,872 | $509 |
| Xarelto | 87 | $44,338 | $510 |
| Brilinta | 85 | $37,789 | $445 |
| Multaq | 47 | $37,345 | $795 |
| Vascepa | 114 | $33,892 | $297 |
| Bystolic | 142 | $29,119 | $205 |
| Lyrica | 59 | $25,445 | $431 |
| Benicar Hct | 55 | $25,440 | $463 |
| Crestor | 51 | $23,619 | $463 |
| Corlanor | 46 | $19,873 | $432 |
| Praluent | 16 | $19,357 | $1,210 |
| Prasugrel | 35 | $15,131 | $432 |
| Jardiance | 17 | $10,838 | $638 |
| Dexilant | 29 | $9,686 | $334 |
| Amitiza | 25 | $9,361 | $374 |
| Coreg | 22 | $8,665 | $394 |
| Atorvastatin | 482 | $7,772 | $16 |
| Nexium | 21 | $7,381 | $351 |
| Omega-3 Acid Ethyl Esters | 34 | $7,065 | $208 |
| Welchol | 12 | $6,975 | $581 |
| Edarbyclor | 23 | $6,832 | $297 |
| Metoprolol | 251 | $6,211 | $25 |
| Potassium Chloride | 182 | $6,111 | $34 |
| Rosuvastatin | 129 | $5,943 | $46 |
| Symbicort | 20 | $5,739 | $287 |
| Esomeprazole Magnesium | 31 | $5,299 | $171 |
| Trintellix | 14 | $4,973 | $355 |
| Exforge | 14 | $4,424 | $316 |
| Tekturna Hct | 18 | $4,407 | $245 |
| Valsartan | 209 | $4,376 | $21 |
| Olmesartan-Hydrochlorothiazide | 26 | $4,334 | $167 |
| Linzess | 12 | $4,144 | $345 |
| Amiodarone | 125 | $3,973 | $32 |
| Alogliptin-Metformin | 15 | $3,625 | $242 |
| Clopidogrel | 248 | $3,533 | $14 |
| Digoxin | 59 | $3,390 | $57 |
| Celecoxib | 24 | $2,939 | $122 |
| Diltiazem 24hr Er | 109 | $2,890 | $27 |
| Trilipix | 11 | $2,819 | $256 |
| Tolterodine Tartrate Er | 19 | $2,727 | $144 |
| Propranolol Hcl Er | 22 | $2,623 | $119 |
| Valsartan-Hydrochlorothiazide | 130 | $2,605 | $20 |
| Yosprala | 13 | $2,587 | $199 |
| Isosorbide Dinitrate | 21 | $2,451 | $117 |
| Propafenone | 48 | $2,428 | $51 |
| Nitroglycerin | 78 | $2,195 | $28 |
| Coumadin | 17 | $2,029 | $119 |
| Carvedilol | 280 | $1,898 | $7 |
| Amlodipine Besylate | 299 | $1,757 | $6 |
| Triazolam | 12 | $1,572 | $131 |
| Metoprolol | 230 | $1,543 | $7 |
| Losartan | 156 | $1,533 | $10 |
| Midodrine | 15 | $1,491 | $99 |
| Isosorbide Mononitrate Er | 70 | $1,359 | $19 |
| Clonidine | 123 | $1,324 | $11 |
| Levothyroxine | 51 | $1,292 | $25 |
| Losartan-Hydrochlorothiazide | 107 | $1,240 | $12 |
| Diltiazem 24hr Cd | 27 | $1,188 | $44 |
| Amlodipine-Valsartan | 29 | $1,116 | $38 |
| Fenofibrate | 24 | $1,111 | $46 |
| Furosemide | 239 | $1,038 | $4 |
| Niacin Er | 12 | $1,020 | $85 |
| Tresiba Flextouch U-100 | 11 | $985 | $90 |
| Butalbital-Acetaminophen-Caffe | 19 | $972 | $51 |
| Megestrol Acetate | 25 | $911 | $36 |
| Voltaren | 15 | $888 | $59 |
| Omeprazole | 49 | $868 | $18 |
| Ramipril | 83 | $765 | $9 |
| Hydralazine | 46 | $752 | $16 |
| Bisoprolol | 18 | $748 | $42 |
| Tamsulosin | 16 | $728 | $46 |
| Digox | 27 | $697 | $26 |
| Nitrostat | 26 | $686 | $26 |
| Cartia Xt | 30 | $660 | $22 |
| Memantine | 23 | $630 | $27 |
| Fenofibrate | 26 | $602 | $23 |
| Warfarin | 49 | $593 | $12 |
| Diltiazem | 25 | $590 | $24 |
| Rizatriptan | 12 | $582 | $48 |
| Pantoprazole | 44 | $579 | $13 |
| Irbesartan | 15 | $539 | $36 |
| Lisinopril | 104 | $530 | $5 |
| Gabapentin | 30 | $522 | $17 |
| Flecainide Acetate | 18 | $519 | $29 |
| Benazepril-Hydrochlorothiazide | 18 | $518 | $29 |
| Simvastatin | 89 | $514 | $6 |
| Alprazolam | 82 | $509 | $6 |
| Toprol Xl | 11 | $507 | $46 |
| Metformin | 98 | $442 | $5 |
| Chlorthalidone | 15 | $442 | $29 |
| Hydrochlorothiazide | 97 | $437 | $5 |
| Spironolactone | 46 | $420 | $9 |
| Benazepril | 38 | $394 | $10 |
| Enalapril Maleate | 11 | $387 | $35 |
| Escitalopram | 50 | $378 | $8 |
| Nifedipine Er | 15 | $374 | $25 |
| Pravastatin | 21 | $374 | $18 |
| Lorazepam | 95 | $369 | $4 |
| Ranitidine | 33 | $351 | $11 |
| Sertraline | 52 | $311 | $6 |
| Atenolol | 57 | $271 | $5 |
| Zolpidem | 41 | $251 | $6 |
| Pioglitazone | 25 | $248 | $10 |
| Trazodone | 11 | $235 | $21 |
| Meclizine | 12 | $231 | $19 |
| Montelukast | 26 | $219 | $8 |
| Doxazosin Mesylate | 16 | $216 | $13 |
| Isosorbide Mononitrate | 24 | $197 | $8 |
| Hydrocodone-Acetaminophen | 12 | $181 | $15 |
| Famotidine | 36 | $180 | $5 |
| Clonazepam | 13 | $171 | $13 |
| Diazepam | 23 | $135 | $6 |
| Klor-Con 10 | 13 | $134 | $10 |
| Meloxicam | 26 | $131 | $5 |
| Alfuzosin Hcl Er | 11 | $129 | $12 |
| Lisinopril-Hydrochlorothiazide | 12 | $121 | $10 |
| Glimepiride | 14 | $113 | $8 |
| Finasteride | 15 | $107 | $7 |
| Buspirone | 15 | $99 | $7 |
| Alendronate | 23 | $98 | $4 |
| Azithromycin | 14 | $98 | $7 |
| Paroxetine | 14 | $72 | $5 |
| Methimazole | 12 | $66 | $6 |
| Terazosin | 12 | $55 | $5 |
| Citalopram Hbr | 12 | $54 | $4 |
| Chlorhexidine Gluconate | 11 | $36 | $3 |
2016: 132 drugs
| Letairis | 19 | $157,760 | $8,303 |
| Ranexa | 239 | $122,191 | $511 |
| Eliquis | 178 | $86,107 | $484 |
| Repatha Sureclick | 58 | $63,631 | $1,097 |
| Crestor | 164 | $61,425 | $375 |
| Pradaxa | 112 | $53,639 | $479 |
| Uloric | 125 | $49,066 | $393 |
| Entresto | 115 | $46,790 | $407 |
| Benicar Hct | 94 | $33,514 | $357 |
| Vascepa | 126 | $32,083 | $255 |
| Multaq | 40 | $30,387 | $760 |
| Xarelto | 57 | $28,644 | $503 |
| Effient | 65 | $28,163 | $433 |
| Brilinta | 61 | $28,002 | $459 |
| Bystolic | 154 | $25,036 | $163 |
| Benicar | 40 | $18,700 | $467 |
| Nexium | 49 | $13,922 | $284 |
| Lyrica | 39 | $10,643 | $273 |
| Dexilant | 39 | $10,089 | $259 |
| Corlanor | 22 | $8,743 | $397 |
| Coreg | 26 | $8,561 | $329 |
| Omega-3 Acid Ethyl Esters | 39 | $8,273 | $212 |
| Exforge | 23 | $7,390 | $321 |
| Lanoxin | 20 | $7,350 | $367 |
| Atorvastatin | 415 | $7,218 | $17 |
| Amitiza | 21 | $6,951 | $331 |
| Welchol | 12 | $6,747 | $562 |
| Namenda Xr | 18 | $6,501 | $361 |
| Metoprolol | 224 | $6,316 | $28 |
| Zetia | 12 | $5,871 | $489 |
| Prevacid | 14 | $5,491 | $392 |
| Valsartan | 162 | $5,204 | $32 |
| Rosuvastatin | 40 | $4,814 | $120 |
| Edarbyclor | 12 | $4,720 | $393 |
| Digoxin | 82 | $4,549 | $55 |
| Savaysa | 13 | $4,353 | $335 |
| Alogliptin | 20 | $3,985 | $199 |
| Clopidogrel | 300 | $3,969 | $13 |
| Dutoprol | 12 | $3,951 | $329 |
| Tekturna Hct | 17 | $3,840 | $226 |
| Amiodarone | 132 | $3,550 | $27 |
| Potassium Chloride | 188 | $3,519 | $19 |
| Isosorbide Dinitrate | 38 | $3,391 | $89 |
| Nitrostat | 110 | $3,166 | $29 |
| Savella | 11 | $3,079 | $280 |
| Celecoxib | 21 | $2,940 | $140 |
| Propranolol Hcl Er | 29 | $2,775 | $96 |
| Trilipix | 12 | $2,499 | $208 |
| Diltiazem 24hr Er | 83 | $2,485 | $30 |
| Valsartan-Hydrochlorothiazide | 99 | $2,402 | $24 |
| Alogliptin-Metformin | 13 | $2,342 | $180 |
| Amlodipine-Valsartan-Hctz | 15 | $1,949 | $130 |
| Prempro | 12 | $1,932 | $161 |
| Metoprolol | 265 | $1,900 | $7 |
| Nitro-Dur | 12 | $1,849 | $154 |
| Fenofibrate | 34 | $1,826 | $54 |
| Propafenone | 36 | $1,794 | $50 |
| Ramipril | 95 | $1,780 | $19 |
| Escitalopram | 88 | $1,771 | $20 |
| Carvedilol | 255 | $1,717 | $7 |
| Amlodipine Besylate | 277 | $1,627 | $6 |
| Candesartan Cilexetil | 17 | $1,517 | $89 |
| Levothyroxine | 72 | $1,515 | $21 |
| Midodrine | 11 | $1,443 | $131 |
| Coumadin | 15 | $1,431 | $95 |
| Losartan | 129 | $1,382 | $11 |
| Niacin Er | 14 | $1,301 | $93 |
| Isosorbide Mononitrate Er | 69 | $1,230 | $18 |
| Losartan-Hydrochlorothiazide | 77 | $1,126 | $15 |
| Fenofibrate | 15 | $1,122 | $75 |
| Bisoprolol | 28 | $1,074 | $38 |
| Nitroglycerin | 17 | $1,047 | $62 |
| Triazolam | 13 | $1,045 | $80 |
| Synthroid | 15 | $994 | $66 |
| Enalapril Maleate | 21 | $962 | $46 |
| Propranolol | 11 | $955 | $87 |
| Clonidine | 115 | $951 | $8 |
| Amlodipine-Valsartan | 12 | $945 | $79 |
| Hydralazine | 50 | $932 | $19 |
| Tamsulosin | 29 | $901 | $31 |
| Furosemide | 292 | $876 | $3 |
| Diltiazem 24hr Cd | 46 | $748 | $16 |
| Zolpidem | 64 | $657 | $10 |
| Irbesartan | 27 | $642 | $24 |
| Ibandronate | 14 | $640 | $46 |
| Pantoprazole | 46 | $622 | $14 |
| Metformin | 97 | $577 | $6 |
| Lisinopril | 119 | $576 | $5 |
| Ranitidine | 39 | $533 | $14 |
| Digox | 17 | $527 | $31 |
| Digitek | 13 | $512 | $39 |
| Alprazolam | 77 | $511 | $7 |
| Hydrocodone-Acetaminophen | 18 | $508 | $28 |
| Omeprazole | 29 | $504 | $17 |
| Nifedipine Er | 16 | $494 | $31 |
| Warfarin | 41 | $477 | $12 |
| Fenofibrate | 17 | $472 | $28 |
| Cartia Xt | 22 | $454 | $21 |
| Hydrochlorothiazide | 102 | $439 | $4 |
| Simvastatin | 77 | $436 | $6 |
| Spironolactone | 44 | $425 | $10 |
| Benazepril | 31 | $380 | $12 |
| Diltiazem | 14 | $379 | $27 |
| Lorazepam | 76 | $371 | $5 |
| Buspirone | 23 | $363 | $16 |
| Sertraline | 62 | $360 | $6 |
| Atenolol | 47 | $360 | $8 |
| Megestrol Acetate | 12 | $331 | $28 |
| Klor-Con M20 | 12 | $311 | $26 |
| Memantine | 14 | $299 | $21 |
| Sotalol | 24 | $289 | $12 |
| Pravastatin | 18 | $289 | $16 |
| Fluoxetine | 19 | $278 | $15 |
| Lactulose | 12 | $242 | $20 |
| Trazodone | 27 | $235 | $9 |
| Gabapentin | 17 | $213 | $13 |
| Chlorthalidone | 14 | $210 | $15 |
| Klor-Con 10 | 16 | $203 | $13 |
| Pioglitazone | 25 | $196 | $8 |
| Diazepam | 15 | $191 | $13 |
| Primidone | 22 | $182 | $8 |
| Triamterene-Hydrochlorothiazid | 14 | $156 | $11 |
| Montelukast | 17 | $143 | $8 |
| Pentoxifylline | 12 | $139 | $12 |
| Famotidine | 18 | $136 | $8 |
| Glimepiride | 14 | $135 | $10 |
| Alendronate | 17 | $126 | $7 |
| Allopurinol | 11 | $125 | $11 |
| Isosorbide Mononitrate | 21 | $115 | $5 |
| Paroxetine | 21 | $80 | $4 |
| Lamotrigine | 12 | $60 | $5 |
| Ibuprofen | 14 | $53 | $4 |
2015: 118 drugs
| Ranexa | 224 | $104,273 | $466 |
| Letairis | 11 | $78,829 | $7,166 |
| Crestor | 201 | $65,479 | $326 |
| Pradaxa | 142 | $57,978 | $408 |
| Eliquis | 83 | $33,969 | $409 |
| Xarelto | 80 | $32,416 | $405 |
| Vascepa | 123 | $27,864 | $227 |
| Bystolic | 144 | $23,757 | $165 |
| Benicar Hct | 67 | $21,127 | $315 |
| Uloric | 51 | $21,096 | $414 |
| Brilinta | 47 | $20,288 | $432 |
| Nexium | 60 | $17,743 | $296 |
| Multaq | 31 | $17,670 | $570 |
| Effient | 40 | $14,824 | $371 |
| Benicar | 52 | $14,735 | $283 |
| Diovan | 49 | $13,677 | $279 |
| Dexilant | 45 | $12,885 | $286 |
| Omega-3 Acid Ethyl Esters | 42 | $9,615 | $229 |
| Welchol | 19 | $9,391 | $494 |
| Exforge | 27 | $8,472 | $314 |
| Namenda Xr | 21 | $7,350 | $350 |
| Atorvastatin | 402 | $6,954 | $17 |
| Celebrex | 13 | $6,286 | $484 |
| Celecoxib | 35 | $6,240 | $178 |
| Lyrica | 22 | $6,161 | $280 |
| Edarbyclor | 21 | $6,119 | $291 |
| Valsartan | 94 | $5,874 | $62 |
| Metoprolol | 175 | $5,752 | $33 |
| Livalo | 18 | $5,424 | $301 |
| Oseni | 14 | $5,093 | $364 |
| Prevacid | 14 | $4,692 | $335 |
| Exforge Hct | 12 | $4,448 | $371 |
| Janumet | 13 | $4,396 | $338 |
| Amiodarone | 130 | $4,318 | $33 |
| Lanoxin | 21 | $4,217 | $201 |
| Clopidogrel | 350 | $4,032 | $12 |
| Isosorbide Dinitrate | 51 | $3,479 | $68 |
| Propafenone | 75 | $3,174 | $42 |
| Potassium Chloride | 133 | $2,975 | $22 |
| Tekturna Hct | 16 | $2,899 | $181 |
| Zetia | 12 | $2,834 | $236 |
| Valsartan-Hydrochlorothiazide | 87 | $2,811 | $32 |
| Tekturna | 11 | $2,757 | $251 |
| Savella | 12 | $2,743 | $229 |
| Digoxin | 59 | $2,674 | $45 |
| Fenofibrate | 34 | $2,504 | $74 |
| Amlodipine-Atorvastatin | 13 | $2,470 | $190 |
| Ramipril | 111 | $2,465 | $22 |
| Midodrine | 13 | $2,356 | $181 |
| Niacin Er | 15 | $1,812 | $121 |
| Nitrostat | 105 | $1,740 | $17 |
| Amlodipine Besylate | 244 | $1,734 | $7 |
| Digox | 31 | $1,733 | $56 |
| Propranolol Hcl Er | 26 | $1,705 | $66 |
| Prempro | 12 | $1,698 | $141 |
| Metoprolol | 267 | $1,693 | $6 |
| Carvedilol | 263 | $1,673 | $6 |
| Levothyroxine | 65 | $1,627 | $25 |
| Diltiazem 24hr Er | 57 | $1,432 | $25 |
| Synthroid | 26 | $1,341 | $52 |
| Losartan | 139 | $1,331 | $10 |
| Diltiazem 24hr Cd | 37 | $1,311 | $35 |
| Digitek | 24 | $1,276 | $53 |
| Paroxetine | 27 | $1,257 | $47 |
| Isosorbide Mononitrate Er | 66 | $1,240 | $19 |
| Coumadin | 14 | $1,211 | $87 |
| Propranolol | 19 | $1,085 | $57 |
| Tamsulosin | 29 | $1,036 | $36 |
| Zolpidem | 61 | $1,029 | $17 |
| Clonidine | 120 | $923 | $8 |
| Cartia Xt | 31 | $873 | $28 |
| Escitalopram | 76 | $871 | $11 |
| Furosemide | 209 | $776 | $4 |
| Bisoprolol | 29 | $775 | $27 |
| Losartan-Hydrochlorothiazide | 40 | $769 | $19 |
| Warfarin | 67 | $745 | $11 |
| Hydralazine | 40 | $743 | $19 |
| Simvastatin | 112 | $669 | $6 |
| Enalapril Maleate | 15 | $665 | $44 |
| Irbesartan | 31 | $622 | $20 |
| Voltaren | 13 | $607 | $47 |
| Hydrocodone-Acetaminophen | 22 | $583 | $27 |
| Lisinopril | 116 | $558 | $5 |
| Diltiazem Er | 12 | $538 | $45 |
| Hydrochlorothiazide | 86 | $527 | $6 |
| Lorazepam | 82 | $467 | $6 |
| Fenofibrate | 17 | $458 | $27 |
| Metformin | 88 | $454 | $5 |
| Sertraline | 81 | $431 | $5 |
| Pravastatin | 21 | $415 | $20 |
| Klor-Con 10 | 16 | $411 | $26 |
| Oxycodone | 11 | $376 | $34 |
| Benazepril | 36 | $372 | $10 |
| Sotalol | 32 | $344 | $11 |
| Pantoprazole | 23 | $342 | $15 |
| Atenolol | 40 | $304 | $8 |
| Meclizine | 14 | $282 | $20 |
| Alprazolam | 58 | $277 | $5 |
| Omeprazole | 20 | $257 | $13 |
| Spironolactone | 42 | $248 | $6 |
| Metoprolol-Hydrochlorothiazide | 11 | $240 | $22 |
| Pioglitazone | 28 | $236 | $8 |
| Glimepiride | 14 | $233 | $17 |
| Ranitidine | 17 | $222 | $13 |
| Trazodone | 37 | $214 | $6 |
| Pentoxifylline | 12 | $194 | $16 |
| Diazepam | 23 | $189 | $8 |
| Primidone | 11 | $179 | $16 |
| Chlorthalidone | 13 | $178 | $14 |
| Isosorbide Mononitrate | 24 | $167 | $7 |
| Metformin Hcl Er | 21 | $134 | $6 |
| Buspirone | 17 | $119 | $7 |
| Gabapentin | 11 | $113 | $10 |
| Verapamil Er | 13 | $105 | $8 |
| Lamotrigine | 12 | $68 | $6 |
| Tramadol | 14 | $46 | $3 |
| Citalopram Hbr | 11 | $27 | $2 |
| Meloxicam | 11 | $23 | $2 |
2014: 124 drugs
| Ranexa | 270 | $106,585 | $395 |
| Letairis | 14 | $94,727 | $6,766 |
| Crestor | 194 | $54,096 | $279 |
| Pradaxa | 114 | $41,750 | $366 |
| Diovan | 139 | $36,504 | $263 |
| Eliquis | 58 | $23,550 | $406 |
| Benicar Hct | 77 | $21,965 | $285 |
| Xarelto | 56 | $17,345 | $310 |
| Vascepa | 82 | $17,240 | $210 |
| Multaq | 33 | $16,552 | $502 |
| Effient | 51 | $15,425 | $302 |
| Nexium | 45 | $14,911 | $331 |
| Bystolic | 109 | $14,156 | $130 |
| Uloric | 31 | $12,862 | $415 |
| Lovaza | 47 | $12,314 | $262 |
| Exforge | 51 | $12,212 | $239 |
| Celebrex | 30 | $11,378 | $379 |
| Dexilant | 49 | $10,748 | $219 |
| Exforge Hct | 26 | $8,786 | $338 |
| Clopidogrel | 404 | $8,693 | $22 |
| Benicar | 30 | $8,559 | $285 |
| Atorvastatin | 417 | $8,193 | $20 |
| Welchol | 21 | $8,005 | $381 |
| Nesina | 21 | $7,505 | $357 |
| Advair Diskus | 25 | $7,483 | $299 |
| Brilinta | 17 | $5,803 | $341 |
| Coreg Cr | 12 | $5,384 | $449 |
| Amiodarone | 99 | $5,323 | $54 |
| Metoprolol | 112 | $5,216 | $47 |
| Edarbyclor | 25 | $5,170 | $207 |
| Plavix | 13 | $5,045 | $388 |
| Tekturna Hct | 26 | $4,432 | $170 |
| Valsartan-Hydrochlorothiazide | 62 | $4,272 | $69 |
| Prevacid | 14 | $4,222 | $302 |
| Livalo | 17 | $4,108 | $242 |
| Cymbalta | 14 | $3,989 | $285 |
| Janumet | 12 | $3,531 | $294 |
| Spiriva | 12 | $3,520 | $293 |
| Fenofibrate | 29 | $3,473 | $120 |
| Trilipix | 14 | $3,072 | $219 |
| Tekturna | 18 | $3,062 | $170 |
| Midodrine | 12 | $3,037 | $253 |
| Potassium Chloride | 108 | $2,776 | $26 |
| Propafenone | 62 | $2,724 | $44 |
| Diltiazem 24hr Er | 97 | $2,717 | $28 |
| Clonidine | 13 | $2,634 | $203 |
| Pioglitazone | 45 | $2,560 | $57 |
| Digoxin | 47 | $2,549 | $54 |
| Carvedilol | 244 | $2,531 | $10 |
| Niaspan | 12 | $2,530 | $211 |
| Lyrica | 13 | $2,508 | $193 |
| Amlodipine Besylate | 254 | $2,403 | $9 |
| Ramipril | 105 | $2,324 | $22 |
| Valsartan | 13 | $2,316 | $178 |
| Amlodipine-Atorvastatin | 12 | $2,312 | $193 |
| Savella | 12 | $2,309 | $192 |
| Isosorbide Dinitrate | 28 | $2,254 | $80 |
| Lanoxin | 14 | $2,183 | $156 |
| Digox | 40 | $1,963 | $49 |
| Metoprolol | 232 | $1,878 | $8 |
| Losartan-Hydrochlorothiazide | 97 | $1,632 | $17 |
| Losartan | 98 | $1,527 | $16 |
| Synthroid | 35 | $1,509 | $43 |
| Paroxetine | 27 | $1,261 | $47 |
| Simvastatin | 123 | $1,086 | $9 |
| Escitalopram | 46 | $1,026 | $22 |
| Hydralazine | 46 | $1,006 | $22 |
| Propranolol Hcl Er | 21 | $997 | $47 |
| Clonidine | 115 | $996 | $9 |
| Levothyroxine | 52 | $987 | $19 |
| Irbesartan | 30 | $951 | $32 |
| Betamethasone Dipropionate | 12 | $885 | $74 |
| Pravastatin | 29 | $856 | $30 |
| Nitrostat | 56 | $849 | $15 |
| Fenofibrate | 22 | $840 | $38 |
| Isosorbide Mononitrate Er | 33 | $770 | $23 |
| Propranolol | 16 | $768 | $48 |
| Bisoprolol | 30 | $768 | $26 |
| Warfarin | 66 | $711 | $11 |
| Furosemide | 169 | $678 | $4 |
| Gabapentin | 47 | $656 | $14 |
| Tamsulosin | 17 | $624 | $37 |
| Amlodipine Besylate-Benazepril | 11 | $614 | $56 |
| Lansoprazole | 18 | $597 | $33 |
| Zolpidem | 60 | $593 | $10 |
| Metformin | 81 | $584 | $7 |
| Benazepril | 47 | $550 | $12 |
| Hydrochlorothiazide | 90 | $490 | $5 |
| Lisinopril | 58 | $489 | $8 |
| Temazepam | 12 | $481 | $40 |
| Omeprazole | 32 | $479 | $15 |
| Sertraline | 67 | $472 | $7 |
| Polyethylene Glycol 3350 | 16 | $456 | $29 |
| Atenolol | 57 | $452 | $8 |
| Allopurinol | 37 | $445 | $12 |
| Enalapril Maleate | 34 | $396 | $12 |
| Cartia Xt | 14 | $381 | $27 |
| Sotalol | 20 | $365 | $18 |
| Lorazepam | 61 | $333 | $5 |
| Triamterene-Hydrochlorothiazid | 20 | $313 | $16 |
| Meclizine | 17 | $290 | $17 |
| Isosorbide Mononitrate | 26 | $282 | $11 |
| Terazosin | 28 | $263 | $9 |
| Alendronate | 16 | $259 | $16 |
| Hydrocodone-Acetaminophen | 11 | $243 | $22 |
| Glyburide | 18 | $242 | $13 |
| Spironolactone | 28 | $212 | $8 |
| Famotidine | 18 | $209 | $12 |
| Ranitidine | 17 | $189 | $11 |
| Diazepam | 24 | $155 | $6 |
| Chlorthalidone | 12 | $149 | $12 |
| Alprazolam | 22 | $148 | $7 |
| Buspirone | 19 | $147 | $8 |
| Fluoxetine | 15 | $143 | $10 |
| Glimepiride | 15 | $142 | $9 |
| Pantoprazole | 14 | $128 | $9 |
| Pramipexole Dihydrochloride | 11 | $123 | $11 |
| Verapamil Er | 12 | $108 | $9 |
| Tramadol | 20 | $95 | $5 |
| Metformin Hcl Er | 17 | $92 | $5 |
| Lamotrigine | 11 | $76 | $7 |
| Chlorhexidine Gluconate | 11 | $74 | $7 |
| Verapamil | 12 | $66 | $6 |
| Meloxicam | 11 | $59 | $5 |
2013: 125 drugs
| Ranexa | 257 | $93,676 | $364 |
| Crestor | 160 | $42,474 | $265 |
| Diovan | 111 | $31,047 | $280 |
| Pradaxa | 102 | $30,060 | $295 |
| Clopidogrel | 346 | $22,025 | $64 |
| Xarelto | 77 | $21,598 | $280 |
| Effient | 70 | $18,681 | $267 |
| Benicar Hct | 71 | $15,432 | $217 |
| Celebrex | 43 | $13,776 | $320 |
| Lovaza | 62 | $13,509 | $218 |
| Bystolic | 104 | $12,908 | $124 |
| Exforge | 60 | $12,054 | $201 |
| Plavix | 49 | $11,939 | $244 |
| Dexilant | 60 | $11,292 | $188 |
| Nexium | 34 | $11,266 | $331 |
| Atorvastatin | 317 | $10,960 | $35 |
| Multaq | 31 | $9,755 | $315 |
| Diovan Hct | 34 | $9,513 | $280 |
| Exforge Hct | 35 | $7,804 | $223 |
| Benicar | 30 | $7,765 | $259 |
| Eliquis | 21 | $7,470 | $356 |
| Valsartan-Hydrochlorothiazide | 67 | $6,770 | $101 |
| Advair Diskus | 23 | $6,018 | $262 |
| Trilipix | 25 | $5,558 | $222 |
| Metoprolol | 131 | $5,205 | $40 |
| Coreg Cr | 15 | $5,144 | $343 |
| Januvia | 18 | $5,142 | $286 |
| Brilinta | 14 | $4,767 | $341 |
| Propafenone | 36 | $4,349 | $121 |
| Tekturna Hct | 26 | $4,140 | $159 |
| Livalo | 11 | $3,995 | $363 |
| Zetia | 15 | $3,955 | $264 |
| Fenofibrate | 25 | $3,677 | $147 |
| Carvedilol | 274 | $3,574 | $13 |
| Niaspan | 15 | $3,515 | $234 |
| Viibryd | 14 | $3,386 | $242 |
| Vascepa | 15 | $3,281 | $219 |
| Amlodipine Besylate | 232 | $3,244 | $14 |
| Micardis | 12 | $3,212 | $268 |
| Ambien Cr | 12 | $3,114 | $259 |
| Janumet | 12 | $3,104 | $259 |
| Escitalopram | 59 | $3,103 | $53 |
| Spiriva | 11 | $3,043 | $277 |
| Ramipril | 145 | $2,721 | $19 |
| Vytorin | 12 | $2,587 | $216 |
| Clonidine | 13 | $2,581 | $199 |
| Cymbalta | 11 | $2,474 | $225 |
| Potassium Chloride | 89 | $2,401 | $27 |
| Losartan-Hydrochlorothiazide | 98 | $2,359 | $24 |
| Amiodarone | 116 | $2,299 | $20 |
| Losartan | 103 | $2,247 | $22 |
| Tekturna | 16 | $2,065 | $129 |
| Amlodipine-Atorvastatin | 12 | $1,965 | $164 |
| Savella | 12 | $1,939 | $162 |
| Diltiazem 24hr Er | 72 | $1,928 | $27 |
| Amlodipine Besylate-Benazepril | 26 | $1,880 | $72 |
| Midodrine | 12 | $1,828 | $152 |
| Simvastatin | 162 | $1,766 | $11 |
| Pioglitazone | 24 | $1,718 | $72 |
| Metoprolol | 204 | $1,661 | $8 |
| Synthroid | 35 | $1,519 | $43 |
| Isosorbide Dinitrate | 16 | $1,514 | $95 |
| Fenofibrate | 18 | $1,485 | $83 |
| Isosorbide Mononitrate Er | 49 | $1,274 | $26 |
| Hydralazine | 34 | $1,108 | $33 |
| Warfarin | 81 | $1,046 | $13 |
| Propranolol | 34 | $975 | $29 |
| Clonidine | 96 | $968 | $10 |
| Nitrostat | 75 | $958 | $13 |
| Furosemide | 180 | $897 | $5 |
| Diltiazem 24hr Cd | 26 | $895 | $34 |
| Fenofibrate | 19 | $873 | $46 |
| Metformin | 86 | $866 | $10 |
| Lanoxin | 15 | $820 | $55 |
| Bisoprolol | 17 | $811 | $48 |
| Lisinopril | 73 | $803 | $11 |
| Lansoprazole | 12 | $761 | $63 |
| Omeprazole | 40 | $739 | $18 |
| Benazepril | 56 | $727 | $13 |
| Irbesartan | 12 | $716 | $60 |
| Megestrol Acetate | 21 | $707 | $34 |
| Hydrochlorothiazide | 82 | $677 | $8 |
| Nitroglycerin Patch | 16 | $662 | $41 |
| Digox | 59 | $652 | $11 |
| Gabapentin | 35 | $640 | $18 |
| Glyburide | 30 | $639 | $21 |
| Metolazone | 20 | $605 | $30 |
| Meclizine | 32 | $597 | $19 |
| Enalapril Maleate | 54 | $591 | $11 |
| Cartia Xt | 15 | $584 | $39 |
| Zolpidem | 71 | $560 | $8 |
| Atenolol | 54 | $536 | $10 |
| Sotalol | 22 | $528 | $24 |
| Lisinopril-Hydrochlorothiazide | 16 | $485 | $30 |
| Levothyroxine | 32 | $452 | $14 |
| Allopurinol | 40 | $413 | $10 |
| Voltaren | 11 | $412 | $37 |
| Hydrocodone-Acetaminophen | 19 | $411 | $22 |
| Pravastatin | 14 | $401 | $29 |
| Spironolactone | 26 | $390 | $15 |
| Quinapril | 11 | $361 | $33 |
| Montelukast | 13 | $361 | $28 |
| Polyethylene Glycol 3350 | 12 | $343 | $29 |
| Amox Tr-Potassium Clavulanate | 11 | $342 | $31 |
| Alendronate | 19 | $317 | $17 |
| Bumetanide | 16 | $302 | $19 |
| Lorazepam | 50 | $300 | $6 |
| Klor-Con 10 | 15 | $299 | $20 |
| Sertraline | 35 | $280 | $8 |
| Acebutolol | 12 | $258 | $22 |
| Klor-Con 8 | 12 | $231 | $19 |
| Triamterene-Hctz | 17 | $229 | $13 |
| Isosorbide Mononitrate | 20 | $228 | $11 |
| Verapamil Er | 16 | $226 | $14 |
| Digoxin | 23 | $222 | $10 |
| Terazosin | 18 | $219 | $12 |
| Pantoprazole | 16 | $215 | $13 |
| Famotidine | 16 | $192 | $12 |
| Hydroxyurea | 11 | $147 | $13 |
| Diazepam | 16 | $114 | $7 |
| Alprazolam | 19 | $89 | $5 |
| Glimepiride | 12 | $86 | $7 |
| Metformin Hcl Er | 13 | $74 | $6 |
| Ranitidine | 13 | $74 | $6 |
| Tramadol | 15 | $62 | $4 |
Money from drug and device companies
$5,011 in 2025
| 2025 | 21 | 140 | None | $5,011 |
| 2024 | 26 | 131 | $100 | $3,865 |
| 2023 | 28 | 176 | $3,650 | $8,580 |
| 2022 | 29 | 226 | $22,277 | $31,276 |
| 2021 | 32 | 232 | $21,730 | $29,974 |
| 2020 | 21 | 148 | $3,950 | $7,224 |
| 2019 | 24 | 155 | $4,900 | $8,679 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Aveir | $2,078 | 37 payments
|
| Boston Scientific | Rotapro | $586 | 20 payments
|
| Merck Sharp & Dohme | Verquvo | $326 | 12 payments
|
| CVRx | Barostim Neo System | $291 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $260 | 15 payments
|
| Novo Nordisk | Wegovy | $201 | 5 payments
|
See all 140 published payments
| Medtronic | Meals · 2025-12-23 | Corevalve Evolut R | $17 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-12-19 | Lifevest | $5 |
| Biotronik | Meals · 2025-12-17 | Biomonitor | $15 |
| Boston Scientific | Meals · 2025-12-15 | Avvigo Guidance System | $9 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-12-11 | Lifevest | $9 |
| Abbott Laboratories | Meals · 2025-12-10 | Aveir | $11 |
| Abbott Laboratories | Meals · 2025-12-10 | Jot Dx | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-09 | Farxiga | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-05 | Camzyos | $23 |
| Boston Scientific | Meals · 2025-12-04 | Rotapro | $11 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-03 | Kerendia | $19 |
| Abbott Laboratories | Meals · 2025-11-26 | Navitor | $28 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-11-25 | Lifevest | $23 |
| Abbott Laboratories | Meals · 2025-11-25 | Jot Dx | $24 |
| Cleerly | Meals · 2025-11-21 | Cleerly Labs | $59 |
| Abbott Laboratories | Travel · 2025-11-20 | Aveir | $80 |
| Amgen | Meals · 2025-11-14 | Repatha | $33 |
| Merck Sharp & Dohme | Meals · 2025-11-13 | Capvaxive | $29 |
| Boston Scientific | Meals · 2025-11-12 | Rotapro | $25 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Leqvio | $20 |
| CVRx | Meals · 2025-11-11 | Barostim Neo System | $31 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-11-07 | Lifevest | $8 |
| Boston Scientific | Meals · 2025-10-24 | Rotapro | $31 |
| CVRx | Meals · 2025-10-23 | Barostim Neo System | $193 |
| Novo Nordisk | Meals · 2025-10-22 | Wegovy | $27 |
| Boston Scientific | Meals · 2025-10-17 | Watchman Access System | $19 |
| Abbott Laboratories | Meals · 2025-10-17 | Aveir | $52 |
| Merck Sharp & Dohme | Meals · 2025-10-15 | Capvaxive | $34 |
| Abbott Laboratories | Meals · 2025-10-14 | Navitor | $17 |
| Novartis Pharmaceuticals | Meals · 2025-10-08 | Leqvio | $26 |
| Novartis Pharmaceuticals | Meals · 2025-10-08 | Leqvio | $5 |
| Boston Scientific | Meals · 2025-10-07 | Rotapro | $22 |
| Abbott Laboratories | Travel · 2025-10-07 | Aveir | $166 |
| Abbott Laboratories | Travel · 2025-10-07 | Aveir | $54 |
| Abbott Laboratories | Meals · 2025-10-06 | Gallant | $9 |
| Abbott Laboratories | Meals · 2025-10-06 | Gallant | $17 |
| Abbott Laboratories | Meals · 2025-10-06 | Gallant | $7 |
| Abbott Laboratories | Meals · 2025-10-06 | Aveir | $18 |
| Boston Scientific | Meals · 2025-10-04 | Rotapro | $19 |
| Boston Scientific | Meals · 2025-10-03 | Watchman Access System | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-02 | Eliquis | $21 |
| Abbott Laboratories | Meals · 2025-10-02 | Aveir | $72 |
| Pfizer | Meals · 2025-09-30 | Vyndaqel | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-29 | Kerendia | $21 |
| Merck Sharp & Dohme | Meals · 2025-09-22 | Verquvo | $32 |
| Abbott Laboratories | Meals · 2025-09-22 | Navitor | $26 |
| Abbott Laboratories | Meals · 2025-09-19 | Navitor | $13 |
| Amgen | Meals · 2025-09-16 | Repatha | $26 |
| Abbott Laboratories | Meals · 2025-09-15 | Jot Dx | $17 |
| Boston Scientific | Meals · 2025-09-11 | Avvigo Guidance System | $147 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-09 | Jardiance | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-08 | Leqvio | $22 |
| Novartis Pharmaceuticals | Meals · 2025-09-08 | Leqvio | $1 |
| Boston Scientific | Meals · 2025-09-05 | Watchman | $6 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-26 | Lifevest | $8 |
| Abiomed | Meals · 2025-08-26 | None | $148 |
| Merck Sharp & Dohme | Meals · 2025-08-21 | Verquvo | $31 |
| Novartis Pharmaceuticals | Meals · 2025-08-18 | Leqvio | $24 |
| Abbott Laboratories | Meals · 2025-08-18 | Gallant | $23 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $9 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $87 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $72 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $85 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $47 |
| Abbott Laboratories | Travel · 2025-08-18 | Aveir | $256 |
| Abbott Laboratories | Travel · 2025-08-18 | Aveir | $175 |
| Abbott Laboratories | Travel · 2025-08-18 | Aveir | $181 |
| Abbott Laboratories | Travel · 2025-08-18 | Aveir | $9 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-14 | Kerendia | $26 |
| Novo Nordisk | Meals · 2025-08-13 | Wegovy | $29 |
| Novo Nordisk | Meals · 2025-08-12 | Wegovy | $77 |
| Merck Sharp & Dohme | Meals · 2025-08-08 | Verquvo | $6 |
| Boston Scientific | Meals · 2025-08-06 | Rotapro | $26 |
| Boston Scientific | Meals · 2025-08-01 | Rotapro | $29 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-31 | Lifevest | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-29 | Jardiance | $20 |
| Amgen | Meals · 2025-07-28 | Repatha | $22 |
| Boston Scientific | Meals · 2025-07-24 | Rotapro | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-24 | Eliquis | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-24 | Camzyos | $3 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-23 | Kerendia | $20 |
| Boston Scientific | Meals · 2025-07-22 | Rotapro | $4 |
| Merck Sharp & Dohme | Meals · 2025-07-18 | Verquvo | $10 |
| Medtronic | Meals · 2025-07-17 | Micra | $31 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-10 | Lifevest | $8 |
| Boston Scientific | Meals · 2025-07-08 | Rotapro | $15 |
| Abbott Laboratories | Meals · 2025-07-08 | Aveir | $21 |
| Novartis Pharmaceuticals | Meals · 2025-06-25 | Leqvio | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-24 | Eliquis | $20 |
| Teleflex | Meals · 2025-06-19 | Guideliner | $30 |
| Merck Sharp & Dohme | Meals · 2025-06-18 | Verquvo | $33 |
| Novartis Pharmaceuticals | Meals · 2025-06-13 | Leqvio | $4 |
| Abbott Laboratories | Meals · 2025-06-13 | Aveir | $143 |
| Boston Scientific | Meals · 2025-06-12 | Rotapro | $21 |
| Novartis Pharmaceuticals | Meals · 2025-05-30 | Leqvio | $8 |
| Alnylam Pharmaceuticals | Meals · 2025-05-29 | Amvuttra | $24 |
| Boston Scientific | Meals · 2025-05-23 | Rotapro | $34 |
| Novartis Pharmaceuticals | Meals · 2025-05-22 | Leqvio | $26 |
| CVRx | Meals · 2025-05-13 | Barostim Neo System | $33 |
| Amgen | Meals · 2025-05-13 | Repatha | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-12 | Camzyos | $12 |
| Abbott Laboratories | Meals · 2025-05-12 | Aveir | $25 |
| Abbott Laboratories | Meals · 2025-05-08 | Aveir | $146 |
| Novo Nordisk | Meals · 2025-05-07 | Wegovy | $35 |
| Boston Scientific | Meals · 2025-05-06 | Rotapro | $51 |
| Boston Scientific | Meals · 2025-04-30 | Rotapro | $29 |
| CVRx | Meals · 2025-04-30 | Barostim Neo System | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-30 | Jardiance | $19 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-04-29 | Lifevest | $6 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-29 | Farxiga | $77 |
| Reflow Medical | Meals · 2025-04-28 | None | $28 |
| Merck Sharp & Dohme | Meals · 2025-04-25 | Verquvo | $32 |
| Novartis Pharmaceuticals | Meals · 2025-04-24 | Leqvio | $21 |
| Novo Nordisk | Meals · 2025-04-23 | Wegovy | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-21 | Camzyos | $22 |
| Boston Scientific | Meals · 2025-04-17 | Rotapro | $54 |
| Merck Sharp & Dohme | Meals · 2025-04-09 | Verquvo | $33 |
| Novartis Pharmaceuticals | Meals · 2025-04-03 | Leqvio | $9 |
| Amgen | Meals · 2025-04-02 | Repatha | $14 |
| Pfizer | Meals · 2025-04-01 | Eliquis | $19 |
| Reflow Medical | Meals · 2025-03-20 | None | $15 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Leqvio | $20 |
| Amgen | Meals · 2025-03-11 | Repatha | $28 |
| Abbott Laboratories | Meals · 2025-03-11 | Aveir | $50 |
| Merck Sharp & Dohme | Meals · 2025-03-04 | Verquvo | $26 |
| CathWorks | Meals · 2025-02-26 | Ffrangio | $158 |
| Merck Sharp & Dohme | Meals · 2025-02-24 | Verquvo | $25 |
| Medtronic | Meals · 2025-02-20 | Micra | $34 |
| Novartis Pharmaceuticals | Meals · 2025-02-18 | Leqvio | $31 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-02-17 | Lifevest | $23 |
| Abbott Laboratories | Meals · 2025-02-13 | Gallant | $48 |
| Novartis Pharmaceuticals | Meals · 2025-02-12 | Leqvio | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-11 | Eliquis | $21 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-02-04 | Lifevest | $8 |
| Abbott Laboratories | Meals · 2025-01-30 | Esprit | $4 |
| Merck Sharp & Dohme | Meals · 2025-01-29 | Verquvo | $34 |
| Abbott Laboratories | Meals · 2025-01-09 | Jot Dx | $3 |
| Abbott Laboratories | Meals · 2025-01-09 | Jot Dx | $44 |
| Abbott Laboratories | Meals · 2025-01-09 | Jot Dx | $13 |
| Medtronic | Meals · 2025-01-08 | Venaseal | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,865
| Medtronic | Corevalve Evolut R | $903 | 30 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $399 | 11 payments
|
| Abbott Laboratories | Jot Dx | $344 | 7 payments
|
| Boston Scientific | Bodyguardian | $338 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $269 | 7 payments
|
| Novartis Pharmaceuticals | Leqvio | $251 | 12 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $151 | 12 payments
|
| Abiomed | Impella | $150 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $146 | 5 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $120 | 4 payments
|
| Novo Nordisk | Wegovy | $99 | 4 payments
|
| Amgen | Repatha | $88 | 3 payments
|
| Asahi Intecc USA | Peripheral Vascular | $86 | 1 payment
|
| Lexicon Pharmaceuticals | None | $77 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $70 | 3 payments
|
| Pfizer | Vyndaqel | $69 | 3 payments
|
| Gilead Sciences | None | $53 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $44 | 2 payments
|
| Alnylam Pharmaceuticals | Onpattro | $39 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $32 | 1 payment
|
| Philips North America | (Bq9) Coronary Ivus | $27 | 1 payment
|
| Esperion Therapeutics | Nexletol | $26 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $24 | 1 payment
|
| Heartflow | Ffrct | $23 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $20 | 1 payment
|
| W. L. Gore & Associates | Gore Cardioform Septal Occluder | $17 | 1 payment
|
2023: $8,580
| AstraZeneca Pharmaceuticals LP | Farxiga | $4,025 | 17 payments
|
| Boston Scientific | Watchman Flx | $433 | 9 payments
|
| Impulse Dynamics (USA) | Optimizer | $430 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $386 | 13 payments
|
| Medtronic | Micra | $378 | 8 payments
|
| Janssen Pharmaceuticals | Xarelto | $304 | 10 payments
|
| Pfizer | Vyndaqel | $303 | 25 payments
|
| Novartis Pharmaceuticals | Leqvio | $284 | 15 payments
|
| AngioDynamics | Auryon Laser System 100-120 Vac | $266 | 4 payments
|
| Lilly USA | Mounjaro | $259 | 11 payments
|
| Abbott Laboratories | Jot Dx | $242 | 7 payments
|
| Merck Sharp & Dohme | Verquvo | $154 | 7 payments
|
| Abiomed | Impella | $147 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $138 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $137 | 9 payments
|
| Philips Electronics North America | (9266) Elca | $134 | 1 payment
|
| Amgen | Repatha | $73 | 3 payments
|
| HeartFlow | Ffrct | $67 | 3 payments
|
| Scpharmaceuticals | Furoscix | $66 | 3 payments
|
| Alnylam Pharmaceuticals | Onpattro | $58 | 3 payments
|
| Lexicon Pharmaceuticals | Inpefa | $58 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $55 | 2 payments
|
| Esperion Therapeutics | Nexletol | $44 | 2 payments
|
| Actelion Pharmaceuticals US | Uptravi | $39 | 2 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $31 | 1 payment
|
| GE HealthCare | None | $29 | 1 payment
|
| Amarin Pharma | Vascepa | $23 | 1 payment
|
| CVRx | Barostim Neo System | $17 | 1 payment
|
2022: $31,276
| Merck Sharp & Dohme | Verquvo | $14,156 | 18 payments
|
| Medicure Pharma | Aggrastat | $6,433 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $3,219 | 14 payments
|
| Boston Scientific | Versacross Access Solution | $2,931 | 23 payments
|
| Abbott Laboratories | Accent | $1,183 | 18 payments
|
| Abiomed | Impella | $409 | 6 payments
|
| Medtronic | Corevalve Evolut R | $367 | 10 payments
|
| Janssen Pharmaceuticals | Xarelto | $311 | 14 payments
|
| Pfizer | Vyndaqel | $294 | 25 payments
|
| Novartis Pharmaceuticals | Entresto | $273 | 20 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $210 | 8 payments
|
| Actelion Pharmaceuticals US | Opsumit | $179 | 10 payments
|
| Impulse Dynamics (USA) | Optimizer | $177 | 2 payments
|
| Astellas Pharma US | None | $174 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $171 | 14 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $141 | 6 payments
|
| Amarin Pharma | Vascepa | $122 | 5 payments
|
| Amgen | Repatha | $117 | 6 payments
|
| Alnylam Pharmaceuticals | Onpattro | $69 | 3 payments
|
| Novo Nordisk | Ozempic | $58 | 3 payments
|
| HeartFlow | Ffrct | $55 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $50 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $47 | 2 payments
|
| Stryker | Trevo | $30 | 1 payment
|
| Lilly USA | Mounjaro | $28 | 1 payment
|
| Esperion Therapeutics | Nexletol | $24 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $18 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $16 | 1 payment
|
| Bard Peripheral Vascular | None | $15 | 1 payment
|
2021: $29,974
| Merck Sharp & Dohme | Verquvo | $20,146 | 27 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $4,286 | 18 payments
|
| Abbott Laboratories | Allure Crt Pacemaker | $1,090 | 20 payments
|
| Medicure Pharma | Aggrastat | $700 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $524 | 30 payments
|
| Abiomed | Impella | $489 | 10 payments
|
| Amgen | Repatha | $260 | 16 payments
|
| Novo Nordisk | Ozempic | $257 | 10 payments
|
| Novartis Pharmaceuticals | Entresto | $207 | 13 payments
|
| Pfizer | Eliquis | $204 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $203 | 9 payments
|
| Boston Scientific | General Stents | $202 | 4 payments
|
| Philips Electronics North America | (8333) Igt D Coronary | $152 | 1 payment
|
| Penumbra | Indigo System | $150 | 1 payment
|
| Amarin Pharma | Vascepa | $148 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $142 | 6 payments
|
| Sanofi-Aventis U.S. | Multaq | $132 | 6 payments
|
| Actelion Pharmaceuticals US | Uptravi | $130 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $127 | 15 payments
|
| Ge Healthcare | None | $125 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $46 | 2 payments
|
| Medtronic | 3f | $41 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $35 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $31 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $30 | 1 payment
|
| Esperion Therapeutics | Nexletol | $22 | 1 payment
|
| Arbor Pharmaceuticals | Edarbi | $19 | 1 payment
|
| Acist Medical Systems | Rxi Consumables | $18 | 1 payment
|
| iRhythm Technologies | Zio Patch | $16 | 1 payment
|
| Preventice Services | Bg Mini Plus | $15 | 1 payment
|
| CathWorks | Ffrangio | $14 | 1 payment
|
| Astellas Pharma US | Lexiscan | $14 | 1 payment
|
2020: $7,224
| AstraZeneca Pharmaceuticals LP | Farxiga | $4,310 | 17 payments
|
| Janssen Pharmaceuticals | Xarelto | $517 | 24 payments
|
| Abbott Laboratories | Confirm Rx | $479 | 9 payments
|
| Amgen | Corlanor | $297 | 16 payments
|
| Amarin Pharma | Vascepa | $273 | 11 payments
|
| Novo Nordisk | Ozempic | $222 | 11 payments
|
| Abiomed | Impella | $161 | 6 payments
|
| Astellas Pharma US | Lexiscan | $134 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $131 | 12 payments
|
| Novartis Pharmaceuticals | Entresto | $129 | 7 payments
|
| Sanofi-Aventis U.S. | Multaq | $108 | 5 payments
|
| Pfizer | Eliquis | $97 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $90 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $69 | 3 payments
|
| Boston Scientific | Superion | $47 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $42 | 3 payments
|
| Medtronic Vascular | Visia Af | $31 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $31 | 1 payment
|
| Daiichi Sankyo | Injectafer | $22 | 1 payment
|
| CathWorks | Ffrangio System | $19 | 1 payment
|
| Tactile Systems Technology | Flexitouch | $14 | 1 payment
|
2019: $8,679
| Amgen | Repatha | $4,967 | 22 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $900 | 17 payments
|
| Abiomed | Impella | $475 | 10 payments
|
| Janssen Pharmaceuticals | Xarelto | $409 | 25 payments
|
| Abbott Laboratories | Quadra Assura Crt Defibrillator | $355 | 7 payments
|
| Medtronic Vascular | Corevalve Evolut | $292 | 7 payments
|
| Novartis Pharmaceuticals | Entresto | $195 | 11 payments
|
| Novo Nordisk | Levemir | $125 | 2 payments
|
| Boston Scientific | Crossboss | $119 | 2 payments
|
| Gilead Sciences | None | $115 | 10 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $112 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $91 | 4 payments
|
| Cardiovascular Systems | Peripheral Orbital Atherectomy System | $90 | 1 payment
|
| Amarin Pharma | Vascepa | $81 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $68 | 5 payments
|
| Pfizer | Vyndaqel | $65 | 4 payments
|
| Biotronik | None | $65 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $41 | 6 payments
|
| Regeneron Healthcare Solutions | Praluent | $28 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $20 | 1 payment
|
| Cook Medical | Cook Medical Angioplasty | $19 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $16 | 1 payment
|
| Tactile Systems Technology | Flexitouch | $16 | 1 payment
|
| Lilly USA | Trulicity | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca UK Limited · A Phase Iib Two Cohort Randomised Placebo Controlled Double Blind Multicentre Dose Ranging Study of Azd5462 in Stable Patients With Chronic Heart Failure · 2025 | Their institution | $541,597 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) · 2025 | Their institution | $397,963 |
| AstraZeneca UK Limited · A Phase II, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess the Effect of Azd0780 on Ambulatory Blood Pressure in Participants With Atherosclerotic Cardiovascular Disease Or Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol · 2025 | Their institution | $181,295 |
| CSL Behring · Study To Investigate Csl112 in Subjects With Acute Coronary Syndrome Aegis-II · 2019 | Their institution | $164,362 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) · 2024 | Their institution | $153,783 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2024 | Their institution | $143,682 |
| AstraZeneca UK Limited · A Phase Iib Two Cohort,Randomised,Placebo Controlled,Double Blind,Multi Centre,Dose Ranging Study of Azd5462 in Stable Patients With Chronic Heart Failure · 2024 | Their institution | $142,244 |
| Amgen Inc. · A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved Or Mildly Reduced Ejection Fraction and Obesity (Maritime-Hf) · 2025 | Their institution | $116,879 |
| CSL Behring · A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Csl112 in Subjects With Acute Coronary Syndrome · 2022 | Their institution | $111,953 |
| Novartis Pharmaceuticals Corporation · Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease · 2024 | Their institution | $109,501 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2023 | Their institution | $103,968 |
| CSL Behring · A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Csl112 in Subjects With Acute Coronary Syndrome · 2020 | Their institution | $95,130 |
| CSL Behring · A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Csl112 in Subjects With Acute Coronary Syndrome · 2023 | Their institution | $94,779 |
| Novartis Pharmaceuticals Corporation · Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease · 2025 | Their institution | $92,562 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2025 | Their institution | $91,949 |
| Boehringer Ingelheim International GmbH · Easi-Hf Reduced A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial To Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (Bi 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (Hf: Nyha II-IV) and Left Ventricular Ejection Fraction (Lvef) < 40% · 2025 | Their institution | $88,060 |
| Amgen Inc. · A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing Olpasiran Use To Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(A) · 2025 | Their institution | $85,373 |
| Novartis Pharmaceuticals Corporation · Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease · 2023 | Their institution | $84,237 |
| Eli Lilly and Company · A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit · 2023 | Their institution | $83,192 |
| Novo Nordisk AS · 2019 | Their institution | $80,875 |
| Novo Nordisk AS · Wegovy · 2021 | Their institution | $78,969 |
| Novo Nordisk AS · 2020 | Their institution | $78,738 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2022 | Their institution | $75,603 |
| Novo Nordisk AS · Wegovy · 2023 | Their institution | $71,300 |
| CSL Behring · A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Csl112 in Subjects With Acute Coronary Syndrome · 2021 | Their institution | $69,109 |
| Novartis Pharmaceuticals Corporation · Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease · 2022 | Their institution | $64,026 |
| AstraZeneca UK Limited · A Phase Iib Randomized Double Blinded Placebo Controlled Parallel Group Study To Evaluate the Efficacy and Safety of Medi6570 in Participants With A Prior Myocardial Infarction Persistent Inflammation and Elevated N Terminal Prohormone Brain Natriuretic Peptide · 2023 | Their institution | $61,505 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2022 | Their institution | $59,090 |
| CSL Behring · A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Csl112 in Subjects With Acute Coronary Syndrome · 2024 | Their institution | $56,016 |
| Novo Nordisk AS · Wegovy · 2022 | Their institution | $51,549 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular · 2019 | Their institution | $50,626 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2023 | Their institution | $49,862 |
| AstraZeneca UK Limited · A Phase Iib Randomized Double Blinded Placebo Controlled Parallel Group Study To Evaluate the Efficacy and Safety of Medi6570 in Participants With A Prior Myocardial Infarction Persistent Inflammation and Elevated N Terminal Prohormone Brain Natriuretic Peptide · 2022 | Their institution | $48,875 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2024 | Their institution | $47,017 |
| Impulse Dynamics (USA) Inc. · Post Approval Study (Pas) of the Optimizer Smart and Ccm Therapy · 2023 | Their institution | $44,807 |
| Novartis Pharmaceuticals Corporation · Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention Or Peripheral Endovascular Intervention (V-Intervention) · 2025 | Their institution | $41,443 |
| Ionis Pharmaceuticals, Inc. · Is354cs9 · 2025 | Their institution | $40,738 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin for Prevention of Hhf and Death Afte · 2022 | Their institution | $39,037 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit · 2024 | Their institution | $37,040 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial To Determine Impact on Serious Events After Myocardial Infarction Paradise Mi · 2019 | Their institution | $35,430 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit · 2022 | Their institution | $33,998 |
| Merck Sharp & Dohme LLC · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2025 | Their institution | $32,559 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular · 2020 | Their institution | $31,202 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2023 | Their institution | $29,491 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2021 | Their institution | $28,149 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2020 | Their institution | $27,898 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial To Determine Impact on Serious Events After Myocardial Infarction Paradise Mi · 2020 | Their institution | $27,463 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein(A) Lowering With Pelacarsen (Tqj230) on the Progression of Calcific Aortic Valve Stenosis [Lp(A)Frontiers Cavs] · 2025 | Their institution | $26,638 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi · 2020 | Their institution | $25,485 |
| Novo Nordisk AS · Wegovy · 2024 | Their institution | $24,853 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu · 2020 | Their institution | $24,743 |
| Novo Nordisk AS · 2024 | This clinician | $24,613 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein(A) Lowering With Pelacarsen (Tqj230) on the Progression of Calcific Aortic Valve Stenosis [Lp(A)Frontiers Cavs] · 2024 | Their institution | $23,029 |
| Merck Sharp & Dohme Corporation · A Pivotal Phase 3 Randomized, Placebo-Controlled Clinical Study To Evaluate the Efficacy and Safety of the Sgc Stimulator Vericiguat,Mk-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction · 2021 | Their institution | $22,539 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi · 2019 | Their institution | $20,717 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Pelacarsen (Tqj230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2025 | Their institution | $20,500 |
| Eli Lilly and Company · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) · 2024 | This clinician | $20,221 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2024 | Their institution | $19,881 |
| AstraZeneca Pharmaceuticals LP · A Phase Iib Randomized Double Blinded Placebo Controlled Parallel Group Study To Evaluate the Efficacy and Safety of Medi6570 in Participants With A Prior Myocardial Infarction Persistent Inflammation and Elevated N Terminal Prohormone Brain Natriuretic Peptide · 2021 | Their institution | $17,628 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2025 | Their institution | $16,768 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfpef) · 2019 | Their institution | $16,751 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Easi-Hf Reduced A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial To Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (Bi 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (Hf: Nyha II-IV) and Left Ventricular Ejection Fraction (Lvef) < 40% · 2025 | Their institution | $16,692 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfpef) · 2021 | Their institution | $16,603 |
| Eli Lilly and Company · A Study of Ly3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (Hfpef) · 2022 | Their institution | $16,589 |
| Eli Lilly and Company · 2024 | This clinician | $16,300 |
| AstraZeneca Pharmaceuticals LP · A Phase Iib Randomized Double Blinded Placebo Controlled Parallel Group Study To Evaluate the Efficacy and Safety of Medi6570 in Participants With A Prior Myocardial Infarction Persistent Inflammation and Elevated N Terminal Prohormone Brain Natriuretic Peptide · 2022 | Their institution | $15,924 |
| Lexicon Pharmaceuticals, Inc. · 2020 | Their institution | $15,485 |
| AstraZeneca UK Limited · A Phase Iib Randomized Double Blinded Placebo Controlled Parallel Group Study To Evaluate the Efficacy and Safety of Medi6570 in Participants With A Prior Myocardial Infarction Persistent Inflammation and Elevated N Terminal Prohormone Brain Natriuretic Peptide · 2024 | Their institution | $14,940 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk · 2021 | Their institution | $14,843 |
| Impulse Dynamics (USA) Inc. · Assessment of Ccm in Hf With Higher Ejection Fraction (Aim Higher) · 2023 | Their institution | $14,774 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk · 2020 | Their institution | $13,637 |
| Amgen Inc. · Galactic-Hf · 2019 | Their institution | $13,465 |
| Amgen Inc. · Galactic - Hf · 2020 | Their institution | $13,306 |
| Impulse Dynamics (USA) Inc. · Aim Higher Study · 2022 | Their institution | $13,135 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk · 2019 | Their institution | $12,929 |
| AstraZeneca Pharmaceuticals LP · A Long Term Outcomes Study To Assess Statin Residual Risk Reduction With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia · 2020 | Their institution | $12,783 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure (Hfpef) · 2020 | Their institution | $12,595 |
| Amgen Inc. · Fda Mandated Sample Collection · 2019 | Their institution | $10,582 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function · 2019 | Their institution | $10,208 |
| Novartis Pharmaceuticals Corporation · Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction · 2019 | Their institution | $9,804 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit · 2021 | This clinician | $9,400 |
| Boehringer Ingelheim International GmbH · Empagliflozin for Prevention of Hhf and Death Afte · 2023 | Their institution | $8,380 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfpef) · 2020 | Their institution | $8,133 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Gloria Af Registry Phase II III Core · 2019 | Their institution | $7,657 |
| Impulse Dynamics (USA) Inc. · Post Approval Study (Pas) of the Optimizer Smart and Ccm Therapy · 2022 | Their institution | $7,500 |
| Amgen Inc. · Fda Mandated Sample Collection · 2020 | Their institution | $7,348 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit · 2021 | Their institution | $6,481 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial To Determine Impact on Serious Events After Myocardial Infarction Paradise Mi · 2021 | Their institution | $5,255 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfpef) · 2019 | Their institution | $5,083 |
| Novo Nordisk Inc · Ozempic · 2024 | Their institution | $4,800 |
| AstraZeneca UK Limited · A Long Term Outcomes Study To Assess Statin Residual Risk Reduction With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia · 2019 | Their institution | $4,380 |
| Novartis Pharmaceuticals Corporation · An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials To Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated Ldl-C · 2023 | Their institution | $4,175 |
| Impulse Dynamics (USA) Inc. · Post Approval Study (Pas) of the Optimizer Smart and Ccm Therapy · 2025 | Their institution | $4,140 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Parallel Group Active Controlled Study To Evaluate the Efficacy and Safety of Lcz696 Compared To Valsartan on Morbidity and Mortality in Heart Failure Patients Nyha Class II To IV With Preserved Ejection Fraction · 2019 | Their institution | $4,121 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Empagliflozin and Heart Failure (Hfpef) · 2021 | Their institution | $4,066 |
| Novo Nordisk Inc · 2023 | Their institution | $4,000 |
| Eli Lilly and Company · A Study of Ly3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (Hfpef) · 2023 | Their institution | $3,876 |
| AstraZeneca Pharmaceuticals LP · A Phase II, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess the Effect of Azd0780 on Ambulatory Blood Pressure in Participants With Atherosclerotic Cardiovascular Disease Or Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol · 2025 | Their institution | $3,338 |
| Boehringer Ingelheim International GmbH · Empagliflozin for Prevention of Hhf and Death After An Ami · 2024 | Their institution | $3,169 |
| Novartis Pharmaceuticals Corporation · A 24 Week Randomized Double Blind Multi Center Parallel Group Active Controlled Study To Evaluate the Effect of Lcz696 on Nt Probnp Symptoms Exercise Function and Safety Compared To Individualized Medical Management of Comorbidities in Patients With Heart · 2019 | Their institution | $3,000 |
| Novartis Pharmaceuticals Corporation · Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction · 2020 | Their institution | $2,550 |
| Organon Llc · 2025 | Their institution | $2,500 |
| AstraZeneca UK Limited · A Phase II, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess the Effect of Azd0780 on Ambulatory Blood Pressure in Participants With Atherosclerotic Cardiovascular Disease Or Risk Equivalents and Elevated Low-Density Lipoprotein Cholesterol · 2024 | Their institution | $2,475 |
| Eli Lilly and Company · A Study of Ly3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (Hfpef) · 2024 | Their institution | $2,250 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Combined Angiotensin Neprilysin Inhibition With Lcz696 Relative To Enalapril on Central Aortic Stiffness and Ventricular Vascular Coupling in Patients With Heart Failure and Reduced Ejection Fraction · 2019 | Their institution | $1,500 |
| AstraZeneca Pharmaceuticals LP · A Long Term Outcomes Study To Assess Statin Residual Risk Reduction With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia · 2019 | Their institution | $1,442 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2022 | Their institution | $1,349 |
| Novo Nordisk AS · 2021 | Their institution | $1,167 |
| Impulse Dynamics (USA) Inc. · Assessment of Ccm in Hf With Higher Ejection Fraction (Aim Higher) · 2025 | Their institution | $705 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2020 | Their institution | $556 |
| Novartis Pharmaceuticals Corporation · Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial To Determine Impact on Serious Events After Myocardial Infarction Paradise Mi · 2022 | Their institution | $497 |
| Amgen Inc. · Galactic - Hf · 2021 | Their institution | $371 |
| Novartis Pharmaceuticals Corporation · Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease · 2021 | Their institution | $301 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease · 2021 | Their institution | $121 |
| Boehringer Ingelheim International GmbH · Empagliflozin and Heart Failure Hfpef · 2022 | Their institution | $111 |
| Novo Nordisk AS · Wegovy · 2020 | Their institution | $95 |
| Novo Nordisk AS · Wegovy · 2023 | This clinician | $50 |
| Novo Nordisk AS · Wegovy · 2022 | This clinician | $50 |
Checkups this office reported
5 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 96.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 1,430 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 92%That's most of the people this applied to. | 852 |
| Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery PatientsAs Medicare defines this measure | 0% | 335 |
| Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk PatientsAs Medicare defines this measure | 0% | 335 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 1,470 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1942496211
- Licence
- CA A48708California A48708: Current · expires 2027-11-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A487080
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Cardiology (207RC0000X)
- Mailing address
- 18350 Roscoe Bl, #400, Northridge, CA, 91325
- NPI first listed
- 2007-09-20
- NPI last updated
- 2008-04-16
This is when the NPI record was last certified, not a medical board exam.